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ABSTRACT 
Clinical Science Research of the Functional Role of Large Conductance Potassium 
Channels in Selective Destruction of Triple Negative Breast Cancer Cells. 
Gina Sizemore
The preliminary background that puts this research into context is threefold; it is the aggressive 
nature of triple negative breast cancer (TNBC), the complexity surrounding its pathology, and the 
significant lack of targeted treatment for this disease. To clarify the focus of my research, I have 
concentrated on identifying a targeted treatment for TNBC. In the process, I have identified 
cycles of reciprocity between treatment, clinical diagnosis, staging, and pathology that will be 
addressed in smaller papers. However, the weight of this work is in the discovery of a novel 
target for triple negative breast cancer. The value of this research is evidenced by the significant 
discovery of a novel ion channel target that demonstrates selective, targeted destruction of TNBC 
without damage to healthy tissue. The specific research aims and objectives are to first, 
characterize the big conductance calcium and voltage gated potassium channel (BK) in TNBC to 
investigate the apparent contradiction of a depolarized (more positive) resting membrane potential 
within the context of a membrane with overexpression of channels that cause hyperpolarization 
(more negative) in the membrane potential. Secondly, examine hyperpolarization of TNBC cells 
as the mechanism of cell death by severe efflux of potassium 
(K) from the TNBC cell via these overexpressed BK channels. Thirdly, establish the first steps 
for human translational research of this discovery with evaluation of human TNBC tumor 
biopsies for similar overexpression of this BK channel. In summary, the objectives are to fill the 
knowledge gap by demonstrating BK channels are not functional (active) in TNBC [which 
explains why we can have a positive (depolarized) cell that should be more negative
(hyperpolarized) due to the overexpression of the BK channel but is not]. Secondly, demonstrate 
that this overexpression of non-functioning (not-active) channels can be exploited by activating 
those channels and hyperpolarizing the cells with efflux of their potassium from the cell as a 
mechanism for selective (not impacting healthy cells), targeted treatment for TNBC. Finally, 
translating that to a first step evaluation of human TNBC from tumor biopsies.
The additional supportive papers in the scope of this work are in chapter two and chapter four 
surrounding the main work in chapter three. The supportive work in chapter two exists to identify 
the opportunity for electrophysiology as a tool for translating basic science discovery to clinical 
application and is listed as reference [1]. The supportive work in chapter four exposes an 
epidemiologic discovery of a translational gap in the clinical diagnosis of triple negative breast 
cancer (manuscript under review) where ion channels can impact. 
This dissertation interpolates information from the afore mentioned papers by the 
author. As described, chapter two references material from reference [1] and was 
authored as follows: Gina Sizemore1, Brandon Lucke-Wold2, Charles Rosen2, James W. 
Simpkins3, Sanjay Bhatia2, and Dandan Sun4. Chapter three references material from 
the main body of work and was authored as follows:  Gina Sizemore1, Sarah 
McLaughlin2, Mackenzie Newman3, Kathleen Brundage4, Amanda Ammer2, Karen 
Martin2, Elena Pugacheva5, James Coad6, Malcolm D. Mattes7, Han-Gang Yu3. Finally, 
chapter four supports the research with the transition to epidemiology and references 
material authored as follows: Gina Sizemore1, Toni Rudisill2.
In summary, this composition weaves a thread across the clinical translational science 
field intertwining chapter two (paper 1) a methods paper of ion channels and the 
electrophysiology tool, with chapter three (paper 2) the novel discovery of an ion 
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The preliminary background that puts this research into context is threefold; it is the aggressive 
nature of triple negative breast cancer (TNBC), the complexity surrounding its pathology, and 
the significant lack of targeted treatment for this disease. To clarify the focus of my research, I 
have concentrated on identifying a targeted treatment for TNBC. In the process, I have identified 
cycles of reciprocity between treatment, clinical diagnosis, staging, and pathology that will be 
addressed in smaller papers. However, the weight of this work is in the discovery of a novel 
target for triple negative breast cancer. The value of this research is evidenced by the significant 
discovery of a novel ion channel target that demonstrates selective, targeted destruction of TNBC 
without damage to healthy tissue. The specific research aims and objectives are to first, 
characterize the big conductance calcium and voltage gated potassium channel (BK) in TNBC to 
investigate the apparent contradiction of a depolarized (more positive) resting membrane 
potential within the context of a membrane with overexpression of channels that cause 
hyperpolarization (more negative) in the membrane potential. Secondly, examine 
hyperpolarization of TNBC cells as the mechanism of cell death by severe efflux of potassium 
(K) from the TNBC cell via these overexpressed BK channels. Thirdly, establish the first steps 
for human translational research of this discovery with evaluation of human TNBC tumor 
biopsies for similar overexpression of this BK channel. In summary, the objectives are to fill the 
knowledge gap by demonstrating BK channels are not functional (active) in TNBC [which 
explains why we can have a positive (depolarized) cell that should be more negative 
(hyperpolarized) due to the overexpression of the BK channel but is not]. Secondly, demonstrate 




those channels and hyperpolarizing the cells with efflux of their potassium from the cell as a 
mechanism for selective (not impacting healthy cells), targeted treatment for TNBC. Finally, 
translating that to a first step evaluation of human TNBC from tumor biopsies.  
The additional supportive papers in the scope of this work are in chapter two and chapter four 
surrounding the main work in chapter three. The supportive work in chapter two exists to 
identify the opportunity for electrophysiology as a tool for translating basic science discovery to 
clinical application and is listed as reference [1]. The supportive work in chapter four exposes an 
epidemiologic discovery of a translational gap in the clinical diagnosis of triple negative breast 
cancer (manuscript under review) where ion channels can impact. This dissertation interpolates 
information from the afore mentioned papers by the author. As described, chapter two references 
material from reference [1] and was authored as follows: Gina Sizemore1, Brandon Lucke-
Wold2, Charles Rosen2, James W. Simpkins3, Sanjay Bhatia2, and Dandan Sun4. Chapter three 
references material from the main body of work and was authored as follows:  Gina Sizemore1, 
Sarah McLaughlin2, Mackenzie Newman3, Kathleen Brundage4, Amanda Ammer2, Karen 
Martin2, Elena Pugacheva5, James Coad6, Malcolm D. Mattes7, Han-Gang Yu3. Finally, chapter 
four supports the research with the transition to epidemiology and references material authored 
as follows: Gina Sizemore1, Toni Rudisill2.  
In summary, this composition weaves a thread across the clinical translational science field 
intertwining chapter two (paper 1) a methods paper of ion channels and the electrophysiology 
tool, with chapter three (paper 2) the novel discovery of an ion channel target, and the 








Temporal Lobe Epilepsy, Stroke, and Traumatic Brain Injury: Mechanisms of 
Hyperpolarized, Depolarized, and Flow-Through Ion Channels Utilized as Tri-Coordinate 
Biomarkers of Electrophysiologic Dysfunction 
 
The brain is an integrated network of multiple variables that when compromised create a 
diseased state. The neuropathology of temporal lobe epilepsy (TLE), stroke, and traumatic brain 
injury (TBI) demonstrate both similarity and complexity that reflects this integrated variability; 
TLE with its live human tissue resection provides opportunity for translational science to 
demonstrate scale equivalent experimentation between the macroscopic world of clinical disease 
and the microscopic world of basic science. The extended value of this research is that the 
neuroinflammatory abnormalities that occur throughout astrocytes with hippocampal sclerosis 
and damaged or even reversed signaling pathways (inhibition to excitation such as with gaba-
aminobutyric acid) are similar to those seen in post-stroke and TBI models. In evaluation of the 
epilepsy population this interconnectedness of pathology warrants further evaluation with 
collaborative efforts. This review summarizes patterns that could shift experimentation closer to 
the macro level of humanity, but still represent the micro world of genetics, epigenetics, and 
neuro-injury across etiologies of physiologic dysfunction such as TLE, stroke, and TBI with 
evaluation of cell function using electrophysiology. In conclusion we demonstrate the 
plausibility of electrophysiologic voltage and current measurement of brain tissue by patch 
clamp analysis to specify actual electrophysiologic function for comparison to 
electroencephalography in order to aid neurologic evaluation. Finally, we discuss the opportunity 
with multiscale modeling to display integration of the hyperpolarization cyclic-nucleotide gated 
channel, the depolarized calcium channels, and sodium potassium-chloride-one/potassium-




biomarkers with these three forms of neurologic disease at a molecular scale of 
electrophysiologic pathology. 
Recent statistics indicate 50 million people suffer with epilepsy [1]. In adults with focal epilepsy, 
about 50% of them have had a previous brain injury [2]. Approximately 2.3% to 14% of stroke 
patients will develop seizures [3] and temporal lobe epilepsy (TLE) develops at rates inconsistent 
with heritability alone lending credence to underlying brain damage or otherwise dysfunction as 
a contributing feature [4]. A common feature in TLE, stroke, and traumatic brain injury (TBI) is 
the electrophysiologic dysfunction. This review will utilize the common thread of electrical 
biophysics to identify existing knowledge, expose the gaps, and project a plan for future 
research. Although the pathophysiology of epilepsy often begins with the discussion of genetic 
mutations, such as the SCN1A gene mutation with over 350 identified mutations [5], those 
mutations are not consistent across all epilepsy. For example, a specific mutation in the SCN1A 
gene, which affects an alpha1 subunit in the voltage-gated sodium channel, is not compromised 
in all epilepsies and not researched at all in diseases like stroke or TBI. Yet, SCN1A has 
demonstrated a phenotype associated with hemiplegic migraine [6], which is often a symptom in 
TBI. Newer research, at smaller scales, reveals mutations of a variety of genes that encode for 
signal transduction, synaptic transmission, neuronal metabolism and excitability, as well as brain 
development that play a role in disease pathology. In addition, variability in epigenetics 
distributes change that do not alter the original DNA, but create a disease state by alterations like 
methylation, and histone modification that can silence or overexpress proteins. Genes can be 
evaluated with specificity of their protein expression at the tissue injury region. These epigenetic 
contributors are demonstrated across a wide range of epilepsies and show correlation with 




barrier compromise in stroke, ion channelopathy of TLE, and white matter apoptosis and 
necrosis of TBI. This review builds a plan to pull up from the microscopic and pull down from 
the macroscopic to define a place in the middle using a scale of disease evaluation that can be 
communicated between the discovery of basic science and the application of clinical medicine. 
Despite this wealth of knowledge, greater than 30% of epilepsy patients continue to battle with a 
drug resistant seizure disorder while stroke and TBI patients bear the persistent symptoms related 
to the electrophysiologic dysfunction that ultimately reflects neurodegenerative change of 
varying degrees. Neuropathology of electrophysiologic dysfunction is complex and encompasses 
neuro-injury, epigenetics, and genetics. This complexity requires organization of scale to 
evaluate the interdependence and integration of these components. The excitability and inhibition 
balance required for homeostasis can be compromised by signaling cascades, genetics, or system 
failure across multiple neuronal circuits [7]. Therefore, selecting three diverse forms of 
electrophysiologic dysfunction: stroke, traumatic brain injury, and temporal lobe epilepsy - this 
review will discuss their commonality of electrophysiologic dysfunction, the limitations of the 
tools for evaluating electrophysiologic dysfunction, and the benefit of focused analysis with a 
hyperpolarized (HCN) channel, a depolarized calcium (CaV) channel and the sodium-potassium-
chlorideone/potassium-chloride-two (NKCC1/KCC2) co-transporters. They can be correlated 
with the epigenetic expression, RNA and protein analysis to determine biomarkers for improved 
evaluation and targeted drug treatment of these diseases. 
Translational Research 
 A challenge in translational research is application of precise, controlled basic science research 
to the multi-variable clinical reality. Therefore, evaluation across the three diseases of stroke, 




between the complexity of the disease (clinical) and the specificity of individual dysfunctional 
components (basic science). This review utilizes location, morphology, and neuropathology to 
create a context for the discussion.  
Location  
Circulation to the brain arises from both the internal carotid arteries anteriorly and posteriorly 
through the vertebrobasilar artery system [8]. The hippocampus, the focal region of TLE, is fed 
through the posterior system with anterior contribution from the anterior choroidal artery. 
Although, not the only contributor to translational research shortcomings from mouse to clinic 
the vascular diversity requires consideration. The mouse does not evidence the anterior choroidal 
artery seen in humans, but with a smaller surface area reflects a more collateral system compared 
to the more end arterial system of humans. In Figure 1 you see the comparison of the mouse and 
human vascular system. The mouse brain (1A) is created by a novel perfusion technique that 
allows resin casting of the mouse vasculature that maintains exact measurements of vascular 
diameter and length while eroding all other brain tissue to leave only a model of the vascular 
system, no brain tissue. In addition, the casting system maintains the network connections to 
demonstrate the collateral system of vasculature in the mouse brain. Everything in the picuture is 
vasculature. Compare that to the perfusion of the human brain (1B) in CT scan analysis. The end 
arterial system is a striking contrast to the more collateral system seen in the mouse vasculature. 
In (1C) the anterior choroidal artery is marked, as it is the only artery reaching to the 
hippocampus from the arterial system in humans, apart from the recurrent artery of heubner. 
Again, this is contrasted to the more collateral mouse vasculature to the hippocampus, which 




research. However, it is paramount that research of human tissue at this scale be developed to 
offset the limitations of animal models and build on their successes. 
Major injury in stroke most frequently occurs from the anterior system, while TBI injury more 
frequently involves the posterior system through vertebrobasilar dissection. Therefore, TLE 
offers the opportunity of a control disease by virtue of consistent hippocampal location injury for 
evaluation with the variant anterior-posterior hippocampal injury from stroke and TBI. The 
anterior choroidal artery, a branch off the internal carotid, just distal to the posterior 
communicating artery is part of the anterior circulation, which runs deep to the hippocampal 
region. In addition, the recurrent artery of heubner originates from the anterior system. The 
variation between these two structures is consistent in that when one is dominate the other 
balances to a smaller development. The anterior choroidal represents part of the residual 
circulation from our evolutionary past before the posterior circulation developed with our higher 
cortical brain and therefore along with the heubner artery offers an opportunity to compare and 
contrast data with a mouse model in the evaluation of stroke, TBI, and TLE. Though absence of 
the anterior choroidal and heubner artery in mice is not the singular cause for the translational 
difficulty, research can demonstrate key functional variances between a collateral system 
(mouse) and an end artery system (human) in the circulation within a unique vascular region of 
brain.  
Approximately two-thirds of ischemic stroke arises in the anterior circulation with 90% of those 
involving infarct of the MCA [9]. However, despite multiple animal models of MCA injury, we 
have failed to discover new drug therapy or targets that translate to successful clinical 
application. The anterior choroidal artery, which lies proximal to the MCA and the end artery 




develops improved biotechnology to traverse these diverse pathways. In TBI, the most common 
vascular injury is subarachnoid haemorrhage [10] with secondary vascular issues from 
vasospasm or lumen narrowing of arteries from edema or increased intracranial pressure that 
further reduce brain perfusion [11]. Vertebrobasilar dissection is more common than anterior 
dissection in traumatic brain injury. The posterior vasculature diameter is narrow and causes 
difficulty, even under more stable situations such as bypass grafts where new techniques have 
been developed to overcome the disadvantage of these high-flow grafts due to the mismatch in 
vessel diameter between donor and recipient vessels in the posterior circulation [12]. With the 
hippocampal sensitivity to ischemia dissection in the posterior system leads to decreased 
perfusion by both blood loss and arterial narrowing due to acute spasm. The hippocampus is 
sensitive to ischemia and periods of excessive intracranial pressure and blood loss could 
demonstrate more significant injury in an end arterial human system compared to a more 
collateral system. Finally, TLE, which is noted for its hippocampal sclerosis, remains devoid of 
significant vascular evaluation despite our knowledge of glial cell function in maintenance of the 
blood brain barrier and its dysfunction in developing sclerosis. The brain vasculature represents 
the pathway in and out of the neurologic circuitry and is too broad to cover the entire network for 
all three diseases. Therefore, location will be restricted to the vascular distribution of the 
hippocampus which reaches deep into our evolutionary past, yet still offers parameters with 
defined limits for the discussion of stroke, TBI, and TLE within a framework that makes them 
consistent with one another by virtue of location. In addition, it addresses specific gaps in our 
knowledge of glial involved vascular injury in TLE, hippocampal role in cognitive and memory 
decline in TBI, and isolates a specific region for analysis of core versus penumbra injury in 




proper resting membrane potential” [13]. Resting membrane potential and action potential firing 
are key electrophysiologic targets translational research can utilize. 
Electrophysiology 
Neuroimaging is the gold standard evaluation in stroke and TBI and offers benefit in surgical 
planning with TLE. However, despite the benefits of these tools, they fail to establish data that 
connects structural abnormality and electrophysiologic dysfunction in the brain that translates to 
improved clinical outcomes [14]. EEG provides cortical activity markers in real-time [15] which 
augment the time lag in neuroimaging. However, few facilities have compatible tools to perform 
these tests synchronisly and have led to decreased use of electrophysiologic tools in preference to 
BOLD MRI, perfusion CT, and specialized manipulations of scans as accessories to primary 
MRI and CT for many neurologic diseases. Therefore, assessment of neuronal oscillations with 
electroencephalography and ion channel function is a novel way to assess the balance between 
excitatory and inhibitory cortical processes and provide biomarkers for future evaluation and 
treatment. The HCN1 channel, the CaV channel, and the NKCC1/KCC2 cotransporter channels 
are representatives of hyperpolarization, depolarization, and flow through that can create a three-
prong coordinate evaluation of current that can be used as a biomarker to aid evaluation and 
treatment being done with neuroimaging and electrophysiology tools such as EEG. In addition, it 
reflects the opportunity for bioengineering to develop alongside new electrophysiologic 
technologies such as microelectrode arrays, which improve spatial resolution over EEG. These 
data can be correlated with data from electrophysiology (See Figure 2). The glass pipette 
patching an astrocyte (2C) indicates the opportunity electrophysiology offers to bring the 
macroscopic world (2A) the glass pipette electrode and (2B) the microscopic world of an 




function that communicates with a language that is the same in the macroscopic and microscopic 
world. Thus, creating the possibility to translate information between scales of the very small and 
precise (basic science discovery) and scales of the very large and complex (clinical application). 
Morphology 
Morphology evaluation is based on literature, which demonstrated large-scale involvement of 
astrocytes and pyramidal neurons in all three diseases. Astrocytes are an active and reactive 
component of the brain that influences gene expression, extracellular matrix components, and 
metabolism. When injured they display distinct features compared to healthy astroglia in their 
morphology, expansion, and signaling in ischemia [16] as well as TBI [17], and sclerosis in TLE 
[18]. Pyramidal neurons are the most common recipient within the environment of change 
commanded by astrocytes. Specific cell types vary by location which ultimately effects their 
function within those regions and the hippocampus remains a controversial region [19]. In 
addition, ion channel distribution on any given cell differs and contributes variation to the cell 
function. The pyramidal neurons of the CA1 region of the hippocampus are extremely sensitive 
to ischemia and ion channel research continues to evaluate this for mechanism though it is not 
yet well defined [20]. Unlike the L5 pyramidal neurons, which stretch through all five levels of 
the cortex, the CA1 pyramidal neuron structures remain confined to the CA1 hippocampal region 
and offer a specific region for discussion and experiment to isolate changes affected by stroke, 
TBI, and TLE. The diversity of cell structure contributes to the variety of function each cell 
offers to the brain (See Figure 3). It demonstrates the variance of a pyramidal neuron (3A); 
notice the CA1 and CA3 pyramidal neurons, of specific interest within the hippocampus, 
compared to the Layer V(LV) pyramidal neuron. In (3B) the LV pyramidal neuron with its 




the more compact CA1 and CA3 of the hippocampus with their apical branching are designed for 
their local purpose. Research indicates a large percentage of HCN channels are expressed in the 
apical region of pyramidal neurons. The benefit of whole cell patch is it reads the resting 
membrane potential of the entire cell at the soma (3C). The alternate protocols available in whole 
cell patch, such as Ramp protocol (3D) and Pulse protocol (3E) allow evaluation of specific 
electrical changes in the entire cell. Therefore, the hippocampus, with the apical girth of CA1 
and CA3 offers opportunity for significant evaluation with electrophysiology of these 
hyperpolarized channels in epilepsy and other neurologic disease. 
Genetic and epigenetic modifications play a role in the channel construction, and expression of 
the channels discussed in this review. Within the spectrum of each disease the full context of 
those modifications is not yet understood. This review’s purpose is to demonstrate the pathology 
based on the role of the channels within the cell for depolarization, hyperpolarization, and flow 
through or electroneutral current to open further discussion of experiment direction for disease 
specific research evaluating these channels as coupling or co-contributing channels in multiple 
disease pathology. HCN as a hyperpolarizing channel leads to hyperexcitability when it is 
mutated from its normal function, Ca leads to multiple variations of depolarization and 
intracellular activity when it mutates from its normal function, and the electroneutral cotransport 
channels already demonstrated as coupling with sodium and potassium alter their flow-through 
neutral status when they mutate from normal function. Approaching this from a predominantly 
electrophysiologic perspective puts focus on the function of the channels when they are mutated 
or have variant expression more than on the depth of discussion of each mutant variation. A 
mutation either causes the channel to work more effectively, less effectively, or not at all. 




function at all. This review aims to discuss the role of these channels in the broader terms of cell 
function in the context of disease rather than specific mutations for any gene family. 
Figure 3D Demonstrates a Ramp protocol, which is the simplest screening tool to evaluate 
channels that open with depolarization. We have used this protocol in research to demonstrate 
how overexpression does not always tell you what the function will be in the cell. If there is 
overexpression of a specific channel on a scale of 1000 to 1, yet only 5% of channels are open at 
the physiologic state then having overexpression of essentially 1000 doors does not matter. The 
function in the cell does not change if they are not open. Therefore, electrophysiology can give 
us functional data about what is going on in the cell without being distracted by genetic 
mutations that may pose no effect to the function or dysfunction of the cell in the disease. Yet 
equally, when there is abnormal function in the cell researchers can track that dysfunction back 
to its specific components of mutation and expression. 
Neuroinflammation 
The signaling pathways for neuroinflammatory response have been exposed as a contributor to 
pathology in neuro trauma, whether the acute injury of stroke, TBI, or the chronic sclerosis of 
TLE. Research linked NKCC1 signal increase to increased ischemic risk [22]. Inflammation of 
astrocytes, seen in temporal lobe epilepsy, occurs due to excess glutamate through the 
glutamine/glutamate/cycle (GGC) [18]. There is significant change demonstrated in the pathway 
from epileptogenesis through sclerosis in a hippocampal astrocyte cell. Comparable astrocyte 
damage occurs in post-stroke by compromise of the arteries where astrocytes assist in 
maintaining the blood-brain barrier and in TBI with similar compromise of the blood-brain 
barrier where in mouse models it is associated with memory changes [23]. There is glutamate 




to the extracellular space. The neuron then uptakes the glutamine where it is degraded to 
glutamate by phosphate activated glutaminase (PAG) and released back to the extracellular space 
as glutamate to continue the cycle. There are multiple opportunities for the system to fail in this 
cycle from glutamine synthetase deficiency or glial glutamate (GLT-1) transporter dysfunction in 
the astrocyte to neuron dysfunction by excessive release due to (PAG) and the excitatory amino 
acid carrier (EAAC1); all of which contribute to extracellular/intracellular ion gradient shifts that 
disrupt homeostasis. 
Neurodegeneration 
Neurodegeneration is a natural path from the epigenetic contributions of neuroinflammation. The 
degeneration of neural tissue in neurologic disease is not singular in its origin and due to mixed 
contributions of neuroinflammation, gene expression, and ion dysregulation it is difficult to 
determine the cause and direction of pathology [24]. The epigenetic impact of the inflammatory 
process can create signal error or excess that leads to sclerosis and/or blood brain barrier breach 
[25]; just to name a few. New research indicates mitochondrial mechanism with miR-34 
mediated regulation of the blood brain barrier and analysis with bioinformatics indicates several 
gene targets [26]. Research correlating upregulation and down regulation of co-transporter 
channels such as NKCC1 and KCC2 respectively following injury [27] support research of these 
channels in the pathology of stroke, TLE, and TBI where neuro inflammatory processes led to 
neurodegeneration. In addition, inflammation can produce neurodegeneration by abnormal gene 
expression, trigger regulating error, and channel surface expression variation with post-
translational modification. For example, the HCN1 channel has an exposed extracellular 
posttranslational modification where circulating inflammatory signals may contribute to 




HCN1 channel can be found in Lee et al., 2017 [28]. These epigenetic influences of 
neuroinflammation can diverge from neurodegeneration and impact neurogenesis as well. 
Neurogenesis 
Increased ion channel density demonstrated significantly depolarized astrocyte cells in 
hippocampal foci damaged regions (~55 mV) compared with astrocytes in hippocampal 
neurotypical regions (~75 mV) since early channel research [29]. This channel density 
neurogenesis continues in recent research, most notably in new research regarding NKCC1 and 
KCC2 co-transporters where ratio shifts to embryologic conditions indicate again the role of 
channel density in the probability for dysfunction [30]. In addition, the electrophysiologic effect 
of channel density on surface expression, post-translational modification, and signaling 
demonstrate the interconnectedness and circular difficulty of the pathology. The anticipated 
voltages can be calculated by Nernst equation demonstrating the polarity shift that the ratio 
inversion of NKCC1 to KCC2 could create in the membrane potential (see Figure 4). The Nernst 
equation in figure four demonstrates the role that concentration of a single ion can play in 
altering the membrane potential of a cell. With so many basic science variables from gene 
expression to neuroinflammation, neurodegeneration, and neurogenesis it is necessary to find a 
system that reflects the function of them all. Electrophysiology can extract the functional data 
that in turn can be correlated with microscopic science and macroscopic disease. 
Ion Channel Milieu 
Regulation of ion homeostasis is critical to the function of cells. Ion transporters establish that by 
cell volume, voltage influence of membrane potential, and signal transduction [31]. Shifts in 




channels to mediate and avoid excessive cellular edema or dehydration with regulatory volume 
adjustments [32]. Membrane potential is primary in the discussion of cell survival and function. 
Therefore, membrane potential is the necessary starting point. The HCN1 channel with its Ih 
funny current displays a reversed polarity in its biophysical nature with a reversal potential ~ −20 
mV carrying a cation current of both Na+ and K+ that is inward moving at rest [33]. This 
combination along with additional features to be discussed creates an intersection of opportunity 
for interaction with sodium-potassium-chloride cotransporters NKCC1/KCC2. Signal 
transduction pathology disrupts cell homeostasis. It is here where ion channels can create 
significant influence. GABA is one of the most researched contributors to signaling pathways 
and demonstrates the importance of ion channel interaction in the discussion of negatively 
charged ion concentrations, such as Cl- within the cell membrane [34]. 
Hyperpolarized Cyclic-Nucleotide Ion Channels 
Sequencing, Construction, and Function 
HCN role in epilepsy is a function of its isoform’s homomeric or heteromeric channel 
construction, expression, and interaction. There are four HCN isoforms: HCN1, HCN2, HCN3, 
HCN4. The expression of HCN1 is more prevalent in the hippocampus and cortex compared 
with the HCN2, and HCN4 isoforms, which are more prominent in the thalamus and sinoatrial 
node [35]. In discussing the role of HCN channels in epilepsy it is not a singular mutation of the 
channel but rather a combination of channel construction variance as well as altered expression 
which demonstrated epileptic disease in mouse models [35]. In addition, deletion of HCN1 and 




However, the structure of the HCN1 channel is showing significant promise for integrated roles 
with its reversed polarity [37]. The hyperpolarization as opposed to depolarization gating make 
the HCN1 channel an excellent candidate for integrated research with NKCC1 and KCC2 co-
transporter channels along with the depolarization gating of the high voltagegated CaV channels. 
The construction of the HCN1 channel pore has great conservation with that of the K+ channels; 
both contain the glycine-tyrosine-glycine (GYG) as a selectivity filter [38]. The function of the 
HCN1 channel is to operate with reverse polarity and it does this by structural design that allows 
for conformational changes of the pore based on the trigger mechanism. Using cryo-electron 
microscopy (Cryo-EM), researchers demonstrated the alternated gating between 
hyperpolarization and cAMP modulation [37]. We hypothesize that hyperpolarization channels 
like HCN1 in conjunction with inappropriate NKCC1/KCC2 co-transport channel ratios allows 
function gain or inhibition at a more negative membrane potential leading to hyperexcitation, 
epileptogenesis, neuroinflammation and therefore has a high potential link to hippocampal 
astrocytic and pyramidal neuron injury with evidence of electrophysiologic dysfunction either as 
neurodegeneration, hyperexcitation or both in stroke, TBI, and TLE. HCN produces a current 
called funny current, If , in the heart and is considered the pacemaker current. It is often written 
as Ih when discussing its current in the brain. The Ih current is an inward current [39]. Its 
complexity of construction from homomeric to heteromeric, as well as expression of the channel, 
impacts how closely to resting cell membrane potential the channel can be triggered. 
Additionally, reduction in expression as well as complete deletion such as is done in knockout 
mice consistently indicates increased seizure risks and activity in other neurologic disease such 




Channel electrophysiology connects with epilepsy, stroke, and traumatic brain injury by offering 
a context of functional evaluation to these diseases. Each disease has pathology rooted in failing 
cellular processes of which ion channels are a key component. When using an evaluation of scale 
as macroscopic as a complete human disease it is difficult to correlate it with equal scale at the 
basic science level (i.e. discuss the function of a cell, as a whole, rather than a single variable of 
change such as a histone modification that changes the expression of a gene). Each of these 
individual discoveries is important. However, electrophysiology of cell function creates a closer 
equality of scale for translational science because the microscopic data is measured, discussed, 
and analyzed with the same tools as the macroscopic data. Resting membrane potential, 
depolarization, and hyperpolarization states are mandatory tools for a cell’s homeostatic balance. 
In this review we press for the whole homeostatic electrical balance system of the cell to be used 
for representation of the larger scale human disease. It is not equivalent, but it is a starting point 
to begin the translational discourse between clinical and basic science. Ion channels play a role in 
the diverse signaling throughout stroke injury at glial cells, neurons, and the blood brain barrier 
[40]. Traumatic brain injury leads to variant excitotoxicity, which could be evaluated, with 
electrophysiology to better understand the functional changes at the cellular level [41]. Epilepsy 
results in hyperexcitability recorded by electroencephalography and confirmed in 
electrophysiology recording baths at the cellular level by evaluation of ion channel function [42]. 
Experimentation to evaluate these diseases for similarities with channels specific for these 
electrical potentials can establish a baseline for deeper discovery of the disease process. 
Electrophysiology is the translational lane of research that is yet to be completely developed and 




basic science (See Table 1). This electrophysiologic diversity can be evaluated further with 
future research since evidence for all four HCN isoforms in the brain have been described [43]. 
NKCC1 and KCC2 Co-Transporter Ion Channels 
Sequence, Construction, and Function 
Research on variants have associated R952H and R1049C of the KCC2 co-transporter channel 
with idiopathic generalized epilepsy (IGE) [45] a more generalized epilepsy. KCC2 plays a 
dominant role in normal development, influencing factors such as the excitatoryinhibitory signal 
read of GABA [46]. When KCC2 is deficient, especially in relevance to NKCC1, brain 
development is compromised. Intracellular chloride currents show biophysical accumulation 
when the ratio construction of NKCC1 expression is higher compared to KCC2 expression [47]. 
This leads to severe neurologic dysfunction and delay noted due to decreased function of the 
NKCC1/KCC2 co-transporter’s ability to maintain low intracellular Cl- because of mutations at 
SLC12A5 [48]. The fundamental role of Na-KCl cotransporter 1 (NKCC1) and K-Cl 
cotransporter 2 (KCC2) is lost when the expression of each is not regulated properly. In addition, 
the integrated signaling system as it relates to GABA is disrupted [49]. The NKCC1 and KCC2 
provide the Cl- homeostasis voltage within the cell [50], which is why they are pertinent to 
evaluation of hyperpolarization-gated channels like HCN1. 
The deregulation of NKCC1 in epilepsy is demonstrated by the increased association with 
epileptogenesis due to its role in managing the concentration of intracellular chloride [51]. The 
slc12 gene family encodes both NKCC1 and KCC2 and mutations in this gene have been 




couple movement of chloride with Sodium and potassium and have demonstrated pathological 
hyperexcitability in mice with genetic modifications of this gene [52]. 
In models of evaluation these chloride channels demonstrate the detrimental effect of neuroinjury 
on their ratios to one another. Multiple research platforms including ischemic stroke, TLE, and 
subarachnoid hemorrhage (the most common brain injury in TBI) reveal the correlated role 
between disease and damage in these channels. Western blot analysis by Yong Tien, et al (2015) 
revealed multiple neuroinflammatory components following subarachnoid hemorrhage. The 
NKCC1 and KCC2 ratio shifts were significant, demonstrating changes of their protein 
expression [53]. Western blot analysis characterized a decline in KCC2 expression and increase 
expression in NKCC1 following induced subarachnoid hemorrhage in their rat model. 
Topiramate, a frequently used anticonvulsant, effectively reversed those KCC2/NKCC1 
expressions in a dose-dependent fashion. This response is a positive indicator of pharmacologic 
opportunity as we learn more about the integration of these channel functions. 
High Voltage-Gated Calcium Ion Channels 
High voltage-gated calcium ion channels are discussed briefly below due to their connections to 
epilepsy and the role they could play in the development of an integrated computational model of 
ion function for future research. 
HVA calcium channels have five known types, all derived with an original subunit: CaV1 the L-
type, CaV2 including the P/Q-type [CaV2.1] the R-type [CaV2.2] and N-type [CaV2.3], and the 
CaV3 the T-type. These types have been studied with regards to genome structure, mutation, 
pathology, and pharmacology. The results thus far are promising. The P/Q type is the CaV2.1 




They both are linked to IGE. The HVA channel requires higher depolarization, compared to 
LVA channels. Yet, both are linked to IGE, both are pharmacologically responsive, and have 
improved epilepsy outcomes with inhibition in patients [54]. Low Voltage Gated Channels like 
the T-type channels offer the first glimpse of opportunity for hyperpolarized channels and 
negative charge transporters to be linked to IGE. The structural changes and pathology of these 
channels is tied to congenital mutations associated with IGE which raises the question for 
susceptibility to more epigenetic, neuroinflammatory changes linked with more focal epilepsy 
like TLE, post-stroke epilepsy (PSE), and post-traumatic epilepsy (PTE). The voltage-gated 
channels have many polymorphisms that contribute to the mutations leading to structural and 
functional change [55], but alone they do not answer all the questions regarding 
electrophysiologic dysfunction. 
The CaV families, which are the L-type channels [CaV1], P/Q-type [CaV2.1] (R-type and N-
type of CaV2 family not reviewed here), and T-type [CaV3] channels, have defined structure. 
The CaV1 and CaV2 types have an alpha subunit that forms the pore of the channel and a 
gamma, beta, and alpha2delta unit forming the tertiary structure. These channels are closely 
related to the CaV3 channel, which also has an alpha unit pore [56]. Splicing variants of each 
subunit contribute to altered phenotypes associated with epilepsy [57]. These splice variants 
determine biophysical properties and tissue location of channels [58]. 
Current data from both animal models and clinical trials point to CaV2 the P/Q type HVA 
channel, and the CaV3 T-type LVA channel as important, but not alone in their epileptogenesis 
role. These channels are well studied and presented briefly here due to their strong link to IGE 
that could shed light on the genetic contributions to the electropyysiologic dysfunction of TLE, 




relevant [38]. Whether from ischemia, TBI, or epilepsy the rich research database on HVA 
calcium channels can help form a background for baseline computational modeling regarding ion 
gradients. 
Clinical Relevance and Conclusion 
The animal models for stroke, TBI, and TLE are beneficial to science and humanity in our 
growth of knowledge, yet they often fail to translate to improved outcomes in human clinical 
applications. Animal models have demonstrated multiple failures in producing drugs with safety 
and efficacy in humans despite success in preclinical experiments [59]. What are the limitations 
that contribute to this discrepancy in translation from bench science to clinic? 
Limitations of Electrophysiologic Tools 
Unlike Electrocardiograms (ECG/EKG), which are standard of care in heart attack evaluations; 
stroke, with its similarities of ischemia, rarely receives evaluation by an electroencephalogram 
(EEG) until the following day, if at all. EEG gives an electrical reflection of the brain’s activity. 
In focal epilepsy, such as TLE, that can be focal waves or spikes [60]. In addition, electrical 
abnormalities consistent with encephalopathy are often seen in stroke patients when EEG is 
performed. Yet, many rural hospitals do not utilize EEG to monitor patients with these 
neurologic conditions because of limitations in skilled personnel and of the equipment itself. 
Whether evaluation is in a mouse model or a hospital, the spatial discernment sacrificed by 
electroencephalography due to the bony scalp and other confounding obstacles between the 
electrodes and the signal cannot always be overcome by the timing integrity of the machine. 




overcoming these limitations [15]. However, training and validation of the researcher’s 
technique can consume large amounts of research time. 
Overcoming EEG Limitations 
Microelectrode arrays and local field potentials show promise in the prediction and localization 
of preictal activity prior to seizures in TLE [61]. As these tools develop new limitations emerge. 
For example, a micogrid covers a large surface area in a mouse, but in a human in is a very small 
area for analysis. This is where the growth of molecular biology and electropyhsiology targets 
the analysis of these small areas with the precision of basic science. With these developing 
technologies, the opportunity for molecular biology to create biomarkers of electrophysiologic 
dysfunction in diseases such as TLE, stroke, and TBI is present and could prove to be the 
translation required to bring bench science more effectively to the clinic. 
Pharmaceutical Limitations 
Anticonvulsant pharmaceutical products create the first line of defense for clinicians treating 
patients with epilepsy. However, many of the medications are non-linear in their kinetics which 
means their half-life and clearance are dependent upon plasma concentrations which can 
fluctuate, reducing the ability to maintain steady state of the drug. In addition, anticonvulsants 
such as Valproic acid, and Clonazepam are greater than 88% protein bound so they do not cross 
the blood brain barrier well and therefore provide little if any medication to the targeted areas. In 
addition, Valproic acid and similar drugs demonstrate serum protein saturable binding which can 
impact other medications when given simultaneously [62]. Newer anticonvulsants such as 
ethosuximide and topirimate are more promising, yet the disease is far from controlled. Stroke 




medication; tissue plasminogen activator (tPA) that can be used in stroke and that is limited to 
specific time frames, and patient types. Finally, in TBI there are multiple complicating factors 
with medication management due to the complexity of symptoms from post-traumatic stress 
disorder to epilepsy.  
Therefore, improved target evaluation and treatment based on a demonstrated abnormality of 
electrophysiologic dysfunction offers a significant opportunity to identify biomarkers for 
bioengineering and innovative technologies for multiple neurologic diseases. 
Ion Channel Options 
Ion channel targeting offers unchartered opportunity for further evaluation and treatment for 
TLE, stroke and TBI. Research demonstrates the adaptation of neurons across cellular types[63]. 
The integration of channel structure and function with cellular stability is described and accepted 
across research fields, though all the intricacies of how that works are not yet understood. 
Continuing the process of collaborative research evaluating the interactions and correlations of 
multiple variables from genetics to inflammatory response by precise research of atomic 
chemistry at the ion channel level can expose those unknowns at the molecular level. In addition, 
the collaboration of scientists and technology can compile research data that can be integrated at 
unprecedented speeds and with increased safety. The Department of Defense, National Institutes 
of Health (NIH), and other large organizations recognize the increasing need for better outcomes 
for patients suffering with neurologic diseases like TBI, stroke, and TLE. NIH published a notice 
in the NIH guide in 2011 encouraging the scientific community to address the issues of 
predictive failure in preclinical research [64]. The focus to bring basic science to the bedside 
more efficiently, safely, and effectively creates an opportunity for research that can begin at this 




HCN1 channels with its unique polarity, depolarized calcium channels, and NKCC1/ KCC2 ratio 
shifts in neuropathology creates a single variable of interaction that can be modeled in a multi-
scale modeling system with a designed control of homeostasis juxtaposed to the actual cellular 
expression identified by genetic analysis of diseased human tissue. The single constant of a 
homeostatic model that is computerized and easily modified as new data arrives lends itself not 
only to comparison against disease tissue, but also better understanding of homeostasis as we 
start to define the variation within normal. It is against this contrast that we will bridge the gap 
from bench to bedside and create - in real time - questions that can be answered safely and with 
better precision before heading to animal and clinical labs for experimentation. This can reduce 
the time to successful treatment in clinical application and increase efficacy and safety as we 
identify potential mechanisms that lead to neurodegenerative changes. TLE hippocampal 
sclerosis, ischemia in stroke, and blood brain barrier compromise in TBI can establish a baseline 
evaluation of electrophysiologic dysfunction. Then interaction and interdependence of the HCN1 
channel, CaV channel and the NKCC1/KCC2 co-transporter channel can correlate dysfunction 
with structure.  
Building A Mouse Model 
Location/Vascular —A global stroke model in mice creates hippocampal ischemia by way of 
the posterior circulation consistent with cardiac arrest as well as stroke. Mice have more 
collateral vascular systems unlike the end artery system in humans and the divergence of humans 
from that evolutionary past may hold one of the keys to improved biomarker targeting for 
humans. Therefore, comparison of the mouse model hippocampal data to human supplemental 




application and open doors for other neurologic disease discussion such as epilepsy and TBI as 
discussed below. 
Morphology – Pyramidal neurons and astrocyte immunohistochemistry evaluation within the 
hippocampus can be used to demonstrate where - on the cellular structures - inclusion of HCN1 
channels in control, ischemic injury mice, and hemorrhagic injury mice occurs. Further 
immunohistochemistry evaluation of mice from control, ischemia, and hemorrhagic stroke 
groups, triggered to seizure with kainic acid, can be analyzed for HCN1 channel expression prior 
to and after seizure. This further characterizes location and identifies spatial relationships for 
comparison to later human research. HCN1 channels with their extracellular exposed post-
translational modification tail may demonstrate significant changes and prove a key biomarker to 
stabilize the first coordinate of a tricoordinate system. 
Structure – mRNA sequencing and Western blot for protein expression of HCN1 will reveal 
increased or decreased expression changes in hippocampal regions exposed to specific injury. 
Function – Acute fresh tissue for electrophysiologic evaluation with specific voltage data by 
patch clamp on dissected hippocampal tissue can then deliver functional data to correlate with 
specific structure, morphologic, and anatomical data. This precision analysis creates the 
foundation for a model of translational human tissue analysis. 
Supplemental Future Research 
Human Research 
Electrophysiology State of the Art Technique – IRB approved human research that can safely 
evaluate human tissue electrophysiologicaly from initial injury (EEG), through craniotomy and 




Discarded tissue can then be evaluated for its voltage and current by patch clamp analysis to 
specify actual electrophysiologic function for comparison to macro tool evaluation. That 
electrophysiologic data can then be connected with the structural expression of biomarker 
channels demonstrated in spatial localization by immunohistochemistry and total expression of 
mRNA and protein by RT-PCR and western blot. 
Building the Future 
Multi-scale Modeling – Data programmed from the evaluation of the HCN1 hyperpolarizing 
channel, and additional channels such as the depolarizing calcium channels, and the flow through 
NKCC1/KCC2 co-transporter channels to demonstrate what is seen experimentally. This 
programmable data can then be used in simulations of tri-coordinate biomarkers for targeted cell 
therapy as a translational tool for future experiments prior to clinical application trials. 
Summary 
In summary, this reflects the limitations and difficulties of translation between the microscopic 
bench science and the macroscopic world of clinical disease. The need for clinical translational 
science evidenced by the 17-year delay between bench and bedside1 is more evident than ever. 
Electrophysiology offers that translation because it communicates across measures of scale. 
Depolarization in the cell’s resting membrane potential is represented the same way as 
depolarization on an EEG or EKG. It is this connection of depolarization that will be discussed 
in the next chapter both at the microscopic level of basic science and at the macroscopic level of 
disease. In chapter three you will see electrophysiology bridge the translational gap when a 
microscopic ion channel proves to be an electrophysiologic target for treatment of a deadly 





Opening Large-Conductance Potassium Channels Selectively Induced Cell Death of Triple-
Negative Breast Cancer 
 
Background: Unlike other breast cancer subtypes that may be treated with a variety of hormonal 
or targeted therapies, there is a need to identify new, effective targets for triple-negative breast 
cancer (TNBC). It has recently been recognized that membrane potential is depolarized in breast 
cancer cells. The primary objective of the study is to explore whether hyperpolarization induced 
by opening potassium channels may provide a new strategy for treatment of TNBC. 
Methods: Breast cancer datasets in cBioPortal for cancer genomics was used to search for ion 
channel gene expression. Immunoblots and immunohistochemistry were used for protein 
expression in culture cells and in the patient tissues. Electrophysiological patch clamp techniques 
were used to study properties of BK channels in culture cells. Flow cytometry and fluorescence 
microscope were used for cell viability and cell cycle studies. Ultrasound imaging was used to 
study xenograft in female NSG mice.  
Results: In large datasets of breast cancer patients, we identified a gene, KCNMA1 (encoding for 
a voltage- and calcium-dependent large-conductance potassium channel, called BK channel), 
overexpressed in triple-negative breast cancer patients. Although overexpressed, 99% of channels 
are closed in TNBC cells. Opening BK channels hyperpolarized membrane potential, which 
induced cell cycle arrest in G2 phase and apoptosis via caspase-3 activation. In a TNBC cell 
induced xenograft model, treatment with a BK channel opener significantly slowed tumor growth 




Conclusions: Our results support the idea that hyperpolarization induced by opening BK channel 
in TNBC cells can become a new strategy for development of a targeted therapy in TNBC. 
Background  
The main molecular subtypes of breast cancer are termed Luminal A (ER+/HER2-), 
Luminal B (ER+/HER2+/-, higher histological grade, more aggressive than Luminal A), HER2-
enriched (ER-/HER2+), and triple-negative (ER-/PR-/HER2-) [1]. Recent gene expression studies 
further identified five “transcriptional subtypes” of breast cancer: basal-like, HER2-enriched, 
luminal A, luminal B, and normal-like (now thought not to originate from breast cancer) [2]. Up 
to 70% of triple-negative breast cancer (TNBC) have the basal-like gene expression signatures, 
however, a large number of basal-like tumors express ER, PR or HER2 [3]. Further studies on 
molecular signatures, genetics, and genomics have led to the identification of four TNBC subtypes 
(basal-like 1, basal-like 2, mesenchymal, and luminal androgen receptor) [4, 5]. These studies have 
revealed the complexity of breast tumors and generated many new hypotheses for potential 
therapeutic targets for treatment of TNBC.  
TNBC is one of the subtypes of breast cancer with an earlier onset, more aggressive 
metastasis, and lacks the therapies available to ER+, PR+, and HER2+ breast cancers [3]. Five-
year breast cancer survival is significantly reduced with diagnosis of TNBC [6], due largely to 
relatively ineffective therapeutic options [7]. There is therefore a need to identify new, effective 
targets for TNBC. 
All cells maintain a polarized membrane potential (Em), more negative inside than outside 
the cell membrane. Em is essential to the development of action potentials in excitable cells such 




variability of Em in non-excitable epithelial cells and cancer cells as well [8]. Alterations in Em 
(depolarization – i.e. Em becoming more positive, hyperpolarization – Em becoming more 
negative) are now recognized to play a crucial role in controlling the cell cycles [9, 10].  
Using a traditional microelectrode technique, Em was reported to be -13mV in breast 
cancer biopsy specimens from nine women with infiltrating ductal carcinoma, independent of ER 
or PR presence [11]. For comparison, normal human breast epithelial cell Em is near -60mV [11]. 
Thus, Em is depolarized in breast cancer compared to normal breast cells. Using whole-cell patch 
clamp, we found more positive Em in TNBC MDA-MB-231 cells (-39.5mV) than in normal breast 
cells (-66.9 mV) [12]. 
KCNMA1 gene encodes the pore-forming alpha subunit of a voltage- and calcium-gated 
large-conductance potassium channel, called BK (also known as Slo1, Maxi-K, or KCa1.1) 
channel [13, 14]. Previous studies have suggested a contradictory role of KCNMA1 in breast 
cancer proliferation, invasion, and metastasis. Blockade of BK channels can slow proliferation and 
invasion of breast cancer cells [15, 16]. In contrast, studies with anti-tumor compounds revealed 
anti-tumor action as an important result with activation of BK channels in metastatic breast cancer 
cells [17].  
BK channels have to open (activate) to exert their function – hyperpolarizing Em by loss 
of intracellular potassium ions. Therefore, high expression of KCNMA1 does not necessarily 
guarantee high activity because closed channels do not have activity and cannot hyperpolarize the 
cell. Similarly, low expression of KCNMA1 expression levels can have a significant impact if all 
channels are open. Therefore, the strategy to inhibit or activate BK channels can only be decided 




In this work, we present evidence for overexpression of KCNMA1 in TNBC from a large 
dataset. Second, we verify a significant increase in protein expression of BK channels in TNBC 
cell lines and primary TNBC tissues. Third, we provide an answer to an intriguing question 
regarding how breast cancer cells remain depolarized while overexpressing a hyperpolarizing ion 
channel, which should make cell membrane potential more negative. Fourth, we demonstrated that 
opening BK channels hyperpolarizes Em and induces apoptotic death of TNBC cells via apoptosis. 
Fifth, we show that BK channel openers can slow tumor growth in an MDA-MB-231 xenograft 
model in female NSG mice to validate the main in vitro finding. Finally, we show that this new 
approach of using BK channel openers for selective induction of death in TNBC does not impact 
healthy breast tissue and cardiac function. 
Methods  
KCNMA1 gene expression in The Cancer Genomic Atlas (TCGA) database 
KCNMA1 gene expression patterns in primary breast cancer database were analyzed from The 
Cancer Genome Atlas (TCGA) [18] via cBioPortal (http://cbioportal.org ) [19]. Gene expression 
levels from RNA-sequencing data was illustrated in log2-fold of fragments per kilobase of 
transcript per million (FPKM) [20]. 
Cell culture and plasmid transfection 
Human breast adenocarcinoma cells (ER+ MCF7, triple-negative MDA-MB-231/Luc and 
SUM159) were grown in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen), whereas 
triple-negative HCC1143 cells were grown in RPMI (Invitrogen), supplemented with 10% fetal 
bovine serum, 1X Pen/Strep (Gbico 15140). Normal human mammary epithelial cells (MCF10A) 




kit (ATCC). Rat h9c2 cardiac myocytes were purchased from ATCC (CRL-1446), cultured in 
DMEM. 
Cells with 50-70% confluence in 6-well plates were used for transient plasmid (1-2g) 
transfection using Lipofectamine3000 transfection reagent (Invitrogen). Human wild type (hSlo1 
WT) and A313D mutant (hSlo1-A313D) channel cDNA in pcDNA3 mammalian expression vector 
were co-transfected with GFP for verification of expression. 
Patch clamp studies in MDA-MB-231 
Details in whole-cell or perforated (or permeabilized) patch clamp studies in isolated cells 
have been previously reported [21, 22]. Briefly, the cells grown on coverslips were placed in a 
lucite bath with the temperature maintained at 35oC - 37oC. Em and voltage-gated potassium 
currents were recorded using the whole cell patch clamp technique with an Axopatch-700B 
amplifier. Em was measured with DMEM or Tyrode solution and pipette solution. DMEM 
contained physiological ion concentration (in mM): 150Na+, 5K+, 2.0Ca2+ (pH = 7.4). Tyrode 
solution contains (mM): NaCl 140, KCl 5.4, CaCl2 1.8, MgCl2 1, Glucose 5.5, Hepes 5, pH 7.4 
adjusted by NaOH. The pipette solution contained (in mM): 85 KCl, 40 K-Aspartate, 0.1CaCl, 10 
HEPES, pH was adjusted to 7.2 by KOH. The pipettes had a resistance of 2–5 M when filled 
with pipette solution. For perforated patch, amphotericin - B was added to the pipette solution to 
a final concentration of 240g/ml. The whole-cell/perforated patch clamp data were acquired by 
CLAMPEX and analyzed by CLAMPFIT (pClamp 9, Axon/Molecular Device). 
Live cell imaging 
Live cell imaging experiments were performed using a Zeiss Axio Observer A1 inverted 




We used ethidium homodimer-1 (EthD-1, Invitrogen, 0.2-0.5l of 2mM stock to 1ml culture of 
cells in 6-well plates) to label dead cells. Cell count was performed using ImageJ (NIH). 
Western blotting 
Cells were harvested using Radioimmunoprecipitation Assay (RIPA) buffer with 1% 
protease inhibitor cocktail (Sigma). We then sonicated lysates on ice and centrifuged at 12,000xg 
for 10 minutes at 4oC. Tumor tissue was homogenized in RIPA buffer with 1% protease inhibitor 
cocktail (Sigma), then centrifuged at 12,000xg for 10 minutes at 4oC. Supernatant was isolated 
from debris pellet. 
Protein concentration was measured using Bicinchoninic acid assay (BCA) (Thermo 
Fisher). Once protein concentrations were normalized across samples, they were then heated for 
12 minutes at 90oC. Samples were loaded into NuPage 4–12% bis-tris gels (Invitrogen) with 
MOPS running buffer at 70 volts for 100 minutes, then transferred to 0.2 m pore PVDF 
membrane (Thermo Scientific) at 30 volts for one hour in cold room. Next, blots were blocked in 
Licor blocking buffer for one hour, and incubated for 12 hours at 4 degrees with primary antibody 
for either anti-KCNMA1 for epitope 199-213 (Alomone cat# APC-151), anti-caspase-3 (Cell 
Signaling Technology), or anti-Slo1 for c-terminus segment 9-10 (Millipore) at 1:500 dilution. 
The membrane was then washed 3 times for 15 minutes with tris-buffered saline containing 0.1% 
tween-20 (TBS-T). A secondary antibody, IR 800 CW from Licor (1:20,000 dilution) was 
incubated with the membrane at room temperature for one hour. After three 10-minute washes 
with TBS-T, blots were imaged using a Licor Odyssey CLx and image studio software. If residual 




completed and the membrane was re-imaged. Beta-actin primary antibody (Proteintech) and 
IRDye 680RD secondary antibody (Licor) were used as a loading control.  
Immunohistochemistry of patient breast samples 
Experiments involving patient breast samples were approved by West Virginia University 
Institutional Review Board. Formalin-fixed paraffin-embedded (FFPE) breast tumor tissue from 
patients was processed according to vendor’s manual instruction (Biocare) and following a verified 
protocol in the Pathology Laboratory of Translational Medicine at WVU. Briefly, 3m sections 
were deparaffinized on slides, quenched with hydrogen peroxide, and incubated in BK channel 
antibody (Sigma-Aldrich, HPA054648) Sigma at 4oC for 4 minutes. Horseradish peroxidase-
containing secondary antibody (UMap anti-RB, Roche, Diagnostic, Cupertino, CA) was then 
added for 8 minutes and developed using Biocare DAB (brown color). Hematoxylin was used as 
a counterstain (blue color). 
Automated formalin-fixed, paraffin embedded immunohistochemical staining, to evaluate 
tumor antigen expression profiles, is available via the Ventana DISCOVERY automated IHC 
Platform. Breast tumor IHC slides stained with BK channel antibody were examined under an 
Olympus VS-120 slide scanner with a 10X Plan S Apo/0.40 NA objective, equipped with a color 
camera (Pike 505C VS50). The images were analyzed using OlyVIA (Olympus) and ImageJ 
(NIH). Percentage of area staining was used to quantify the protein expression levels in IHC slides. 
Breast tumor induction in NOD scid gamma (NSG) mice 
Female NSG-immunodeficient mice of 4-6 weeks old were purchased from the Jackson 
Laboratory. Experimental procedures and housing of the animals were approved by the 
Institutional Animal Care and Use Committee. Animal were housed in a fully state-of-the-art 




light/dark cycle, temperature control, quality water, clean cages access to food and water), and 
welfare-related policies related to tumor studies (e.g., tumor burden policy). 
Following power analysis, a total of 16 female mice was used, 8 for treatment, 8 for 
controls. For mammary pad injections, pathogen-free luciferase-expressing human breast 
adenocarcinoma cells (MDA-MB-231/Luc, 1-2x106 cells/animal) were injected into the fourth 
inguinal mammary gland of 6- to 8-week-old mice. Primary tumors had formed typically two 
weeks following cell injection. Tumor size was monitor by imaging twice a week. After 
experiment, mice were euthanized by isoflurane overdose (5% to effect or an overdose 100mg/kg 
of sodium pentobarbital), a procedure approved by our IACUC. 
Ultrasound imaging of xenograft tumor in NSG mice  
Details for ultrasound imaging of xenograft tumor in NSG mice have been previously 
reported [21]. Briefly, animals were anesthetized by exposure to 1-3% isoflurane during imaging. 
Imaging was performed weekly over the course of each experiment, typically for 4-6 weeks. 
Tumor volume was imaged by ultrasound imaging (USI) with Vevo2100 Micro-Ultrasound 
System. A 40 or 50 mHz transducer was used, depending on the tumor volume. A 3-dimensional 
(3D) image was acquired with scanning distance of 0.071 mm between images. Vevo software 
then integrated the images into a reconstructed 3D tumor from which the tumor volume was 
obtained. 
BK channel openers 
BMS-191011 (Tocris) and NS11021 (Tocris) were prepared in 10mM DMSO stock. The 
working concentrations of 10-50M contained 1-5l of DMSO in 1 mL DMEM medium, resulting 
in 0.1-0.5% of DMSO, which did not affect TNBC cells (Figure S7). For testing in vivo effects of 




administrated directly into the xenograft grown in mouse via during day time in the animal imaging 
facility. For testing adverse effects of the drug, tail-vein injection was used. 
Scratch (or “wound healing”) assay 
MDA-MB-231 cells were incubated in a 24-well plate. After reaching 70% confluence, the scratch 
(or “wound”) was created using a sterile 200-l pipette tip, defined by the space within two red 
lines (upper left), filled (or “healed”) by migration of cells (upper right). Curved red line indicates 
the marker (shadowed area) used to identify the location of the scratch. 
Caspase-3/7 Green Fluorescence Dye 
CellEvent Caspase-3/7 Green Detection Reagent was obtained from Thermo Fisher (Cat#: 
C10723). Working solution of 1M was used in cell culture. Fluorescence microscopy was used 
to acquire images. Green fluorescence was detected only apoptotic cells. 
Cell cycle analysis using flow cytometry 
Cells were grown to 60-80% confluency in DMEM before drug treatment. Cells were either 
treated with BMS-191011 in DMSO, DMSO alone, or no treatment. After 24-48 hours, cells were 
washed with PBS and incubated with 0.25% trypsin with EDTA (Invitrogen) for 5 minutes at 37oC. 
After combining the resultant solution with 10mL PBS in 15mL tubes, cells were pelleted at 
1000rpm for 6 minutes at 4oC. Cell pellets were resuspended in 200L PBS then added with 
swirling to 2mL ice cold 70% ethanol. These single-cell suspensions were kept at 4oC until further 
processing. 
For flow cytometry, cells were re-pelleted at 1000rpm for 6 minutes before decanting 
ethanol. After resuspension in 2mL PBS and incubation for 1 minute at room temperature, cells 
were pelleted and resuspended in 100L of 0.2% Tween-20 in PBS at room temperature then 




sodium azide was added and cells were pelleted. The solution was then decanted, 10L of RNase 
A (DNase- and protease-free; Thermo Scientific EN0531) in PBS (180g/mL) was added and 
allowed to sit for 15 minutes at room temperature, and 20L of propidium iodide (PI) in PBS 
(50g/mL) was added for 15 minutes. The resultant solution was brought to a volume of 300-
500L using PBS before data collection. 
Samples were analyzed on BD LSRFortessa using BD FACS Diva version 8.0 software.  A 
minimum of 20,000 cells were collected for each sample.  Data analysis was done using FCS 
Express 6.0 flow cytometry software (De Novo Software, Los Angeles CA). Cell cycle fit 
algorithm was selected using the lowest relative chi square value and BAD value < 20%. 
Statistical analysis 
Data were shown as mean  standard deviation (SD) in the text. Bar figures were presented 
as mean  SD using GraphPad (Prism). Student’s t-test and two-way ANOVA (for more than two 
groups) were used for statistical analysis. P<0.05 was considered as statistically significant. Details 
in statistical analysis, such as F values and degree of freedom (DF) when using ANOVA and t 
values when using t-test, are included in the figure legends. 
Results 
1) KCNMA1 gene and protein expression in breast cancer patients 
We used gene expression data (RNA-seq) from 981 breast cancer samples (TCGA Cell 
2015 [23] and TCGA Provisional). In all five subtypes BK channel KCNMA1 gene expression 
levels are dramatically upregulated, comparison to normal breast cells (FPKM ~ 0.7) (Figure 1). 




Using transcriptomics and a targeted proteomics approach, the gene-specific correlation of 
mRNA levels and protein copy number has been well established in human cells and tissues [24]. 
Previous studies have demonstrated that BK channel alpha subunit protein (main subunit forming 
the pore of the channel) is abundantly expressed in MDA-MB-231 cells, weakly expressed in 
MCF7, and nearly undetectable in normal breast epithelial cells MCF10A [15]. Therefore, we set 
out to investigate the protein expression of BK channels in TNBC patients’ tissues. 
Figure 2 shows a representative figure for protein expression of BK channel alpha subunit 
in primary TNBC tissue using an antibody that targets an epitope in the 1st extracellular loop of 
transmembrane domains 1 and 2 (corresponding to amino acid residues 199-213 of rat KCNMA1 
(Alomone Labs).  MDA-MB-231 (MDA231 in the figure) was used as a positive control. Mouse 
brain (MB) known to express BK channels [25, 26] was used as an additional positive control 
(stronger signals in a more sensitive fluorescence image of Western blot). In addition to the 
glycosylated channel protein (around 200kD), there exist smaller fragments recognized by the 
antibody that are likely the proteolyzed C-terminals of the channel protein reported in previous 
studies [27]. The interpretation of the results was confirmed by incubation of the antigen (2B) that 
showed disappearance of the signals in 2A. After total expression signals being normalized to -
actin, BK channel protein expression levels are nearly 14-fold higher in primary TNBC than in 
normal human breast tissue (Normal: 0.345±0.177; TNBC: 4.793±1.074, n=4-6, p<0.001) (2C). 
Figure 2D shows that BK channel proteins are also abundantly expressed in different types of 
TNBC cells (SUM159, HCC1143), but barely detectable in MCF10A normal breast cells. 
To confirm the increased protein expression levels of BK channels in TNBC patients, we 
performed IHC experiments in seven TNBC tissue and three normal breast tissue samples. We 




protein expression in the Human Protein Atlas (Sigma-Aldrich, HPA054648). Supplemental 
Figure 1 shows a normal breast tissue (A) and a TNBC tissue (B). The averaged percentage of 
protein expression area is shown in (C). BK channel protein levels were increased by ~ 9-fold in 
TNBC than in normal breast tissue (TNBC = 3.56±1.33, n=7; Normal = 0.41±0.10, n=3; p<0.01). 
Figure 1 raised several questions: 1) Why are depolarized TNBC cells overexpressing a 
hyperpolarizing BK channel? 2) Are these overexpressed BK channels activated (open)? These 
questions led us to the hypothesis that these overexpressed BK channels are not activated. If this 
hypothesis is correct, then opening these channels can be exploited as a novel strategy for targeted 
therapy in treatment of TNBC. 
For ion channels whose activity is dependent on Em, gene/protein expression levels are not 
intrinsically correlated with channel activity. At the resting Em of the cell, ion channels are active 
when they are open, inactive when they are closed. We therefore set up to investigate biophysical 
properties of BK channels in TNBC cells. 
2) Voltage-dependent activation of BK channels in TNBC cells 
Previously, we showed that the resting Em, which is within the physiological voltage range, 
in MDA-MB-231 cells is depolarized compared to normal mammary epithelial cells (HMEC) 
(Em_MDA-MB-231: about -40mV, Em_HMEC: about-67mV) [12]. To investigate whether BK 
channels in MDA-MB-231 are open at -40mV, we studied biophysical properties of BK channels 
in MDA-MB-231 cells using whole-cell and perforated patch clamp techniques. 
Figure 3A shows the typical BK channel currents activated by the depolarizing pulse 
protocol (below 3A). The currents were confirmed to be generated from BK channels by 




250pM) since it does not affect other ion channels [28]). Figure 3B shows the average voltage-
dependent activation curve of BK channel in eight (8) MDA-MB-231 cells. At -40mV (resting Em 
in MDA-MB-231), only 1% of BK channels are open. 
3) BK channel opener hyperpolarizes Em in MDA-MB-231 cells 
Opening large conductance (>200pS) [29] BK channels causes loss of intracellular K+ ions 
to the outside of the cell, leading to membrane hyperpolarization. In MDA-MB-231 cells, we used 
a potent selective BK channel opener, BMS-191011 (1M) [30] to study how opening BK 
channels may affect cell Em. We found that BMS-191011 (1M) hyperpolarized Em by 15mV 
(Em_con = -30.71±8.20mV, Em_BMS = -45.86±8.95mV, n=8; p<0.01) within 15min of 
application (Figure 3C). IbTX (100nM) did not induce significant change in Em (Em_con = -
30.71±8.20mV, Em_IbTX = -30.86±6.64mV, n=8; p>0.05), but completely reversed 
hyperpolarization induced by BMS-191011 (Em_con = -30.71±8.20mV, Em_BMS+IbTX = -
28.43±7.30mV, n=8; p>0.05) (Figure 3C). The results provided additional evidence that the 
majority of BK channels are closed at Em in MDA-MB-231 cells. 
4) BK channel opener induced death of human TNBC cells 
To test whether hyperpolarization by opening BK channels can induce death of TNBC 
cells, we studied effects of BK channel opener in TNBC cell lines. Treatment of BMS - 191011 at 
20M for two days did not affect normal breast MCF10A cells (Supplemental Fig.2, left panels), 
but dramatically induced cell death of MDA-MB-231 cells (Supplemental Fig.2, middle panels). 
BMS-191011 halted growth of MCF-7 cells but induced death of much fewer cells compared to 




dead/dying cells are 0.92 ± 0.29% (n=5) for MCF10A, 14.76±1.94% (n=5) for MCF-7, and 
63.82±6.21% (n=5) for MDA-MB-231, p<0.0001 (One-way ANOVA).  
To ensure that BMS-191011 induced cell death is via opening BK channels, we used 
another specific BK channel opener, NS11021, which has a different chemical structure [31]. 
Figure 4B shows time - and concentration – dependent effects of NS11021 on the growth of MDA-
MB-231. At day 5, most cells treated with 20M NS11021 were dead (Supplemental Fig.3). For 
the same day, NS11021 induced cell death at different concentration is statistically significant 
compared to untreated group (p<0.0001, n=6). 
To test whether BK channel opener mediated hyperpolarization-induced cell death is 
independent of TNBC subtypes, we studied effects of BMS-191011 on additional TNBC cell lines, 
SUM159 (Basal A, like MDA-MB-231) and HCC1143 (Basal B) [32]. BMS-191011 inhibited cell 
growth of SUM159 (4C) (and Supplemental Fig.4) and HCC1143 (4D) (and Supplemental 
Fig.5) cells in a similar way compared to that in MDA-MB-231. Additional controls were 
performed to rule out the potential side effects of DMSO on the cell growth of TNBC. 
Supplemental Figure 6 shows an example for 0.5% DMSO (maximal volume used in drug 
treatment) that has no effect in cell death of HCC1143. We also tested that DMSO had no effects 
in cell growth of MDA-MB-231 and SUM159 cell lines. 
Additionally, we tested whether a mutated BK channel that is permanently open (A313D), 
leading to hyperpolarization [33] may induce MDA-MB-231 cell death. Supplemental Figure 7 
shows that after 2 days of transfection, 59.4±13.7% (n=5) of MDA-MB-231 cells expressing 
A313D died, in comparison to 17.2±5.3% (n=5) of death in cells expressing wild-type (WT) 




of transfection, all MDA-MB-231 cells expressing A313D were dead, whereas most cells 
expressing WT channels or GFP alone were alive. 
5) BK channel opener induced apoptosis and caspase-3 activation in TNBC  
  To understand the mechanism that mediates hyperpolarization - induced death in TNBC 
cells, we studied apoptosis, a well-studied programmed cell death mechanism. We performed time-
lapse imaging experiment demonstrating that low concentration (1M) of BMS-191011 induced 
rapid cell shrinkage, a distinguished event unique to apoptosis [34], within 20-60min 
(Supplemental Fig.8).  
We also studied effect of BK channel opener in caspase activation, an established 
mechanism and a strong indicator of apoptosis [35]. We first used a fluorescent caspase 3/7 green 
dye to test whether BK channel opener may induce caspase activation in MDA-MB-231. Figure 
5 shows that after 3 days of 10M BMS-191011 treatment (5A), strong fluorescent signals (5B) 
were detected in MDA-MB-231. Furthermore, Figure 5C shows the presence of pro-caspase-3 
protein expression in three TNBC cell lines, MDA-MB-231, HCC1143, and SUM159. BMS-
191011 (20M) treatment for two days induced cleaved caspase-3 expression in MDA-MB-231  
(5D). These results suggested that BK channel opener can induce caspase-3 activation in MDA-
MB-231 cells. Thus, hyperpolarization can induce activation of caspase-3 and apoptosis in TNBC 
cells. 
6) BK channel opener prevented migration of MDA-MB-231 
Majority of breast cancer patients die due to tumor metastasis and one critical step of 
metastasis is migration [36]. If BMS-191011 effectively induced cell death, it may prevent 




“wound heal”) imaging experiment [37]. While control (untreated) MDA-MB-231 cells can 
recover from the scratch within 4 hours (upper), 100nM BMS-191011 prevented migration of 
MDA-MB-231 cells within 4 hours (lower). Similar results were obtained in an additional four 
experiments. 
7) BK channel opener induced arrest in cell cycle G2 phase in MDA-MB-231 
  Figure 6 shows the effect of opening BK channels in MDA-MB-231 cell cycle using flow 
cytometry. In the absence of BMS-191011 treatment, cell distribution in G1/S/G2 phases are 
approximately equal (A), BMS-191011 treatment after 24h resulted in arrest in S/G2 phases 
associated with a decrease distribution in G1 phase (B). After 48h, cells are all arrested in G2 phase 
(C). As a control, we showed that DMSO (1%) had no effects on cell cycle in MDA-MB-231 cells 
after 24h treatment (Supplemental Fig.10). Similar results were repeated in an additional three 
experiments. 
8) BK channel opener induced slower growth of MDA-MB-231 xenograft in NSG mice 
  To test the inhibitory effects of BK channel opener on TNBC tumor in vivo, we generated 
MDA-MB-231 xenograft in female NSG mice at 4-week old age [21]. After a sizable tumor was 
formed (typically after 1-2 weeks of cell injection), BMS-191011 at 100g/kg (or 1-2g/mouse) 
was directly injected into the tumor for better control of the dose and the potential loss of the drug 
due to rapid metabolism in mice. The drug was given twice a week in the treat group. For control 
group, saline was given twice a week. To avoid large variation in tumor sizes due to heterogeneity 
of breast cancer, we selected pairs of tumors (one as a control – injected PBS only, the other treated 
– injected drug in PBS) that had similar tumor sizes, and performed ultrasound imaging for four 




  Figure 7 shows a representative example for three pairs of control and treated tumors. The 
injection of the drug began at week5 when three pairs (C1/T1, C2/T2, and C3/T3) had similar 
tumor sizes, the treated tumor (T) grew significantly slower than the control tumor (C) each week 
(7A). In week 8, averaging data showed a 33% reduction of tumor volume in drug-treated group 
(T= 710±105, n=8) compared to the control group (C=1056±106, n=8) (p<0.05) (7B). 
9) BK channel opener and cardiotoxicity  
 Cardiac toxicity is a major concern in anti-cancer drugs [38]. Supplemental Figure 11 
shows the echocardiograph results for MDA-MB-231 xenograft mice treated with a high dose 
(0.1mg/kg) of BMS-191011 compared to control (PBS treated) mice (n=3). There are no 
significant differences (p>0.05) between the two groups in cardiac function including heart rate, 
ejection fraction, left ventricular mass, and cardiac output.  
 Additionally, we co-cultured MDA-MB-231 with the cardiac myocytes to test the 
hypothesis that BK channel opener can only induce cell death in MDA-MB-231 but not in cardiac 
myocytes due to extremely low expression levels of KCNMA1 gene in the heart.  Supplemental 
Figure 12 shows that BMS-191011 at 20M indeed induced cell death only in MDA-MB-231 
with little effects in cardiac myocytes after six-day incubation.  
Discussion 
In the present work, we showed evidence to support a hypothesis that targeted treatment 
by activation of BK channels - thereby hyperpolarizing the Em - can induce cell death in TNBC 
while sparing healthy breast cells without cardiac toxicity.  We selected a BK channel opener due 
to overexpression of the channels in breast cancer and large conductance of the channel. Opening 




rapid efflux of K+ ions. Extremely low expression of BK channel gene expression in normal breast 
cells and cardiomyocytes ensures selective apoptosis in TNBC and absence of cardiac toxicity by 
BK channel opener. 
Using microarrays, KCNMA1 gene expression was found to increase in several cancers 
including breast cancer [16]. Using RNA-seq data in a large breast cancer dataset in TCGA, we 
found overexpression of KCNMA1 in all subtypes of breast cancer. In principle, our approach of 
using BK opener for selective induction of cell death works for all subtypes of breast cancer. We 
focus on TNBC due to lack of targeted therapy in TNBC. It needs to be emphasized that mutations 
in KCNMA1 gene are rare – only 15 (7 in luminal A, 5 in luminal B, 2 in HER2, 1 in basal subtype) 
in breast cancer, although the gene is overexpressed and the cause of overexpression is unknown.  
We verified that the BK channel alpha-subunit protein levels are significantly increased in 
MDA-MB-231 and in TNBC patient tissues compared to normal primary breast tissues. The 
overexpression of BK channels in breast cancer would intuitively lead to interest in inhibition. 
However, inhibition mandates that channels be active. This creates an apparent contradiction with 
the overexpression of an ion channel that if it were active should make the Em more negative, yet 
our research demonstrates a cell with a more positive (depolarized) resting Em. This contradiction 
can be resolved if the BK channels are not open at resting Em in TNBC. The lack of statistically 
significant correlation of relapse free survival rate with expression confirms the need to look 
beyond channel expression to channel function to answer this question of inhibition or activation. 
We performed patch clamp studies and found that indeed <1% of BK channels are open at 
-40mV, which is near the Em in MDA-MB-231 cells [12]. This result addressed the problem of a 




opened a new idea that opening BK channels in breast cancer cells should hyperpolarize Em, which 
may halt cell growth. 
We tested this concept in three TNBC cell lines, MDA-MB-231, SUM159, and HCC1143, 
representing different subtypes of TNBC. We used two structurally different openers (BMS-
191011 and NS11021) to ensure that any effects seen in cell growth are mediated by BK channel 
opening. Notably, BK channel openers induced more cell death in MDA-MB-231 than in MCF-7 
(a non-metastatic breast cancer cell line). One possible explanation is that BK channel protein 
levels are significantly higher in MDA-MB-231 than in MCF-7. Indeed, using 
immunofluorescence staining BK channels have been previously reported to be abundantly 
expressed in MDA-MB-231, very weak in MCF-7, and undetectable in MCF10A [15]. 
Additionally, we employed a constitutively opened mutant BK channel to demonstrate that 
hyperpolarization is the primary driving force to induce cell death in TNBC cells.  
To explore cellular mechanisms that mediate the hyperpolarization-induced death in TNBC 
cells, we showed in MDA-MB-231 cells early morphology changes (shrinkage) and late activation 
of caspase-3 in MDA-MB-231 cells. Normotonic shrinkage of cells is a hallmark of apoptosis [34]. 
Caspase activation is a well-established pathway in apoptosis [39]. In addition, we showed that at 
low concentration (100nM), BK channel opener was able to prevent cell migration. 
During cell cycle, membrane depolarization is essential for transition of G2-phase to 
mitosis [9, 10]. Induced hyperpolarization during this transition can arrest cell growth by blocking 
DNA synthesis [9, 10]. Indeed, our results demonstrated that hyperpolarization induced by BK 




In three size-matched tumor pairs, BMS-191011 slowed down the growth of xenograft 
tumors every week, indicating that opening BK channels in tumor can inhibit cell growth of TNBC 
cells in vivo.  After four-week treatment, there was a statistical difference between the two groups, 
even using a small number of mice (8 per group) and twice a week drug treatment. Increasing 
number of mice and frequency of drug treatment may likely demonstrate a stronger statistical 
significance with a larger inhibitory effect in xenograft tumor growth. 
A major concern in anti-cancer drugs is cardiotoxicity [38]. The KCNMA1 gene expression 
levels are very low in the heart (FPKM  0.2 to 0.3) [40]. We performed echocardiogram on the 
mice to assess potential cardiac side effects of BK channel opener in cardiac functions. We found 
no significant changes in cardiac functions in treated mice compared to untreated mice. 
Furthermore, in the co-culture of TNBC cells with cardiac myocytes, we showed that BK channel 
opener did not induce significant toxicity in cardiac myocytes, while killing TNBC cells.  
Targeted therapy has significantly increased the survival rate of breast cancer patients, 
while cardiotoxicity remains  an increased risk of cardiovascular disease (such as left ventricular 
dysfunction and heart failure) in breast cancer treatment [41]. For older women (>65 years) 
surviving breast cancer, the leading mortality is cardiovascular disease, not breast cancer itself 
[41].  
 Ion channels play a critical role in the hallmarks of cancer [42]. Gating of voltage-
dependent ion channels are controlled by cell membrane potential (Vm). Opening and closing of 
these channels also change Vm. For example, opening of K+ channels causes membrane 
hyperpolarization (Vm becomes more negative) due to K+ ions flowing out of the cell [43, 44]. On 
the other hand, opening of Ca2+ channels increases calcium influx ([Ca2+]o ~ 1-2mM, [Ca
2+]i ~ 




Calcium homeostasis is an extremely delicate process, disruption of calcium homeostasis triggers 
many pathological events including apoptosis [46, 47]. Many ion channels are overexpressed in 
cancer cells, but nearly undetectable in normal epithelial cells. For example, voltage-dependent 
calcium channels (VGCC) are readily detectable in breast cancer cells [48, 49], but not in human 
healthy mammary epithelial cells . Therefore, we demonstrated that blocking VGCC can 
effectively inhibit growth of breast cancer cells without affecting normal breast cells .  
Recently, voltage-gated potassium channels have attracted cancer investigator for being 
potential targets in cancer therapy [51, 52]. Kv1.3 has gained particular attention due to its low 
expression in the heart, while overexpressed in cancer [53, 54]. We are targeting BK channel since 
it has the largest conductance in the potassium channel family. Opening BK channels therefore 
can induce the largest membrane hyperpolarization, a central strategy to breast cancer cells in 
which membrane potential is depolarized.   BK channel expression levels in heart (RPKM ~0.2) 
is even lower than in normal breast cells (RPKM ~0.7), targeting BK channel activation is 
anticipated to have significantly less effects in cardiac functions. 
Conclusions 
While KCNMA1 genes are overexpressed in all types of breast cancer, targeting it is 
particularly useful for TNBC due to lack of effective pharmacological therapy in TNBC patients. 
We propose a novel approach to inhibit TNBC growth based on depolarized Em and significantly 
increased BK channel gene expression in TNBC. This new strategy is independent of TNBC 





The evidence in this research for targeted treatment of TNBC with this BK ion channel 
demonstrated, not only the novel discovery for treatment possibilities in TNBC, but also the 
significant role electrophysiology can play in granting functional insight to genetic data which 
translates to clinical understanding of disease and future opportunity for application. This next 
section reveals the circle of clinical translation when an epidemiology study shows a multi-gene 
signature test which could identify electrophysiology ion channel targets is not only underutilized 
but may contribute to why there is exponentially increased tumor growth in TNBC patients with 





















Triple Negative Breast Cancer: Exponential Tumor Grade Increase with Age of Diagnosis 
Abstract 
Triple negative breast cancer is an aggressive breast cancer with decreased five-year survival, 
increased risk for recurrence, and higher risk for metastases. Unlike other breast cancers, it has 
no targeted treatment and has heterogenous genetics which make classification and treatment 
difficult. The purpose of our research was to compare triple negative breast cancer to non-triple 
negative breast cancer to identify key epidemiologic factors that might lead to improved basic 
science directives for biomarkers, treatments, and classification. Our research uses the state 
cancer registry to provide the first West Virginia state-wide population evaluation of triple 
negative breast cancer. The research reveals novel results that tumor grade increases 
exponentially with the age at diagnosis. This creates an epidemiological foundation for future 
research to define whether the disease, access to care, biology of aging, or some other factor 
cause this significant finding. In addition, results reveal decreased use of testing that could be 
increased to improve biomarker identification, targeted treatments, and classification of triple 
negative breast cancer. 
Introduction  
World-wide, breast cancer is a leading cause of cancer mortality in women1 and in the United 
States, invasive breast cancer impacts 12.4% of the population of women.2 Breast cancer is a 
diverse disease with five molecular subtypes.  One type is triple negative breast cancer (TNBC), 
a breast cancer where tumors are negative for estrogen receptor, progesterone receptor, and 
Human Epidermal Growth Factor Receptor 2 overexpression.3,4 Because of its heterogeneity, 




recent being the genetic profile classification.5 TNBC is an aggressive disease and is associated 
with a poorer prognosis and 5-year survival rate as there is a higher risk for recurrence and 
metastasis among affected patients.6,7,8  Previous studies have shown that the prevalence of 
TNBC is higher in some demographic groups such as women under 40 years of age and among 
women of black race or Hispanic ethnicity.9,10,11,6,12,7,13,14 The reasons as to why certain 
demographic groups are more affected than others are unknown.  Previous studies have proposed 
that obesity, diet, genetics, socioeconomic, and biological factors may explain differences seen 
among demographic groups in terms of TNBC.11,6,7,15,3,16,8 
Because of the severity of TNBC, there has been an increased interest in investigating 
demographic, diagnostic, and prognostic factors associated with the disease not only nationwide, 
but also in West Virginia.9,8,17  The age-adjusted breast cancer mortality rate among women in 
West Virginia is the 8th highest among states.18  In addition to the high mortality rate, West 
Virginia’s population is somewhat homogenous compared to other states as over 94% of the 
population is White Non-Hispanic;19 thus, racial differences may be observed to a lesser extent.  
However, the population is of lower socioeconomic status and has greater levels of obesity 
compared to most other states.20,21 The state also has a low net migration of residents which 
could indicate that hereditary factors associated with TNBC, such as BRCA mutations, may 
remain present in the population and influence the disease’s prevalence.3,22  
To date, two studies have investigated TNBC in West Virginia.8,17  One study found that West 
Virginia patients had increased representation of advanced tumors at time of diagnosis.17  The 
other study determined that a greater proportion of women with TNBC were under the age of 50 
and that their tumors were larger than non-TNBC patients; TNBC patients also were slightly 




from a university hospital and/or a regional medical center over 15 years ago.  Thus, the purpose 
of this study was to investigate the demographic and diagnostic differences between those 
diagnosed with TNBC compared to non-TNBC utilizing more recent data from the state’s cancer 
registry, which includes all patients diagnosed with breast cancer in the state.  The findings of 
this study could help inform future research in a state where cancer risk and mortality are high.  
METHODS 
Data source 
The primary data source for this analysis was the West Virginia Cancer Registry, which is 
maintained by the West Virginia Department of Health and Human Resources in Charleston, 
WV.  Since 1993, the registry maintains demographic and clinical data on individuals whom are 
diagnosed and treated for cancer within the state.  The registry also includes West Virginia 
residents who were treated outside the state boundary, but retain a West Virginia address.23  The 
registry collects, codes, and maintains these data in accordance to the National Cancer Institute’s 
Surveillance, Epidemiology and End Results Program (SEER).24  The data are de-identified for 
patient confidentiality purposes.   
Study population 
The study population included all West Virginia women who were diagnosed with breast cancer 
(e.g. International Classification of Diseases for Oncology, Third Edition, codes C500-C509) 
from January 1, 2010 thru December 31, 2016. The data years 2010-2016 were selected because 
there were data quality concerns prior to 2010 and 2016 was the most recent data year available. 
Human subject’s protections 






The primary dependent variable was whether an individual was diagnosed with TNBC (e.g. 
dichotomous).  TNBC was defined in accordance to SEER as a breast cancer that is negative for 
estrogen receptors, progesterone receptors, and Human Epidermal Growth Factor Receptor 2 
overexpression.24 Various independent variables were utilized for this analysis which included: 
patient’s age at diagnosis, race, year of diagnosis, stage of cancer at diagnosis, whether their 
cancer metastasized (binary), whether the patient’s ipsilateral axillary lymph nodes were 
implicated (binary), whether the cancer was entirely insitu (binary), tumor grade, whether a 
multigene test was performed on the patient (binary), and whether the patient was diagnosed 
with Paget’s disease of the breast (binary).  The categorization of these variables is shown in 
Table 1.  Race was dichotomized into white or other due the demographics of the state (e.g. it is 
primarily White non-Hispanic).19 For tumor grade, some patients were given a Bloom-
Richardson score.  Those with scores 3-5 were considered low grade.  Those with scores 6-7 or 
8-9 were categorized as moderate and high grade, respectively.  
Analyses 
Because the objective of this study was to compare the characteristics of women in West 
Virginia who were diagnosed with TNBC to other types of breast cancers, several analyses were 
conducted.  The demographic and diagnostic characteristics between those diagnosed with and 
without TNBC were compared via frequencies and percentages.  In order to determine which 
variables were associated with TNBC in patients, both binary and multivariable logistic 
regression analyses were conducted; these types of models were chosen because the outcome 
was dichotomous.25 Unadjusted (i.e. binary) models were ran between each independent variable 
and the outcome.  All multivariable models were adjusted for age group, race, and year of 




adjusted for year and race and the multivariable model for race was only adjusted for year and 
age group).  These models were adjusted for these variables because there are known differences 
with TNBC diagnoses among different age groups and races in other clinical populations.9  Year 
was also adjusted for because of the increasing awareness of TNBC in the literature overtime 
which could potentially influence diagnoses.26  A third set of multivariable models were ran to 
investigate potential effect measure modification.  These models contained the same variables in 
the first multivariable model but also included two interaction terms; there was one interaction 
term between the independent variable of interest and age group and another interaction term 
between the independent variable of interest and race.27 All data management and statistical 
analyses were conducted in SAS/STAT software version 9.4 (Cary, NC) with two sided 
significance level α=0.05.   
RESULTS 
Nearly 13% of the women diagnosed with breast cancer in West Virginia had TNBC (Table 1).  
While nearly 60% of all breast cancer patients were over 60 years of age, a slightly larger 
proportion of women ≤40 years of age were diagnosed with TNBC (7%) compared to those with 
non-TNBC (4%). In regard to race, there was an increased percentage of non-whites (6%) 
diagnosed with TNBC compared to the non-TNBC group (3%). The stage of cancer at diagnosis 
confirmed a more aggressive cancer in TNBC with (4.2%) involving direct and lymph nodes 
compared to non-TNBC (2.7%) and a distant cancer in TNBC (8.1%) compared to distant cancer 
in non-TNBC (5.7%) at time of diagnosis. Metastasis was higher in TNBC (6.9%) compared to 
non-TNBC (5.4%). Tumor grade differed in TNBC patients with 73.1% in high grade compared 
to only 22.6% high grade in non-TNBC. While only 26% of patients with breast cancer received 




Table 2 shows the association between TNBC and demographic and diagnostic criteria. After 
adjusting for race and year, the odds of TNBC diagnoses in women ≤40 was 2.2 times greater 
than the odds of TNBC in women ≥71 years of age.  The odds of a TNBC diagnosis in non-
whites was 71% higher than the odds of TNBC in whites after adjusting for age and year.   
Additionally, it appeared that TNBC was associated with higher tumor grades.  The odds of 
TNBC was 16 times greater in high tumor grades than the odds of TNBC in women with low 
tumor grades at time of diagnosis after adjusting for age, race, and year. Yet, the odds of a TNBC 
diagnoses was 86% lower among those receiving a multigene test compared to the odds of a 
TNBC diagnoses among those not receiving a multigene test. 
Age was an effect modifier of the relationship between TNBC diagnoses and tumor grade (Table 
3). After adjusting for both year and race, the odds of TNBC dramatically increased with more 
severe tumor grades over the age groups. A female under the age of 40 diagnosed with TNBC 
had 5 times greater odds of having a high tumor grade compared to the odds of a woman in the 
same age group diagnosed with TNBC having a low- grade tumor.  However, the odds of TNBC 
for a female ≥71 years of age to be high grade stage was nearly 22 times greater than the odds of 
a TNBC diagnoses for a female in the same age group having a low-grade tumor.  
Age was also an effect modifier of the relationship between TNBC diagnosis and multigene test 
conductance (Table 4). It appears that the conductance of the multigene test decreases with age.  
While there were no differences in women ≤40, after adjusting for year and race, the odds of 
TNBC diagnoses among 41-50 year-olds is 75% lower if multigene test is conducted compared 
to the odds of a TNBC diagnoses among women of the same age who do not receive the 




lower if multigene test is conducted compared to the odds of a TNBC diagnoses among women 
of the same age who do not receive the multigene signature test. 
DISCUSSION 
Several important findings were discovered as a result of this analysis.  First, trends in TNBC 
diagnoses typically seen in other studies were also seen in West Virginia.  Secondly, TNBC 
diagnosis and tumor grade varied by age, which is a novel finding. Thirdly, while multigene 
testing was infrequently performed among all breast cancer patients, there was an inverse 
relationship between age and multigene conductance among TNBC patients specifically.  These 
are important findings especially when considering the previous literature indicating delayed 
diagnoses of breast cancer among West Virginia patients.17   This generates an imperative to 
improve early diagnosis, treatment planning, and cancer typing.  
In relation to the current literature, the findings were consistent with those of previous 
nationwide studies.  The prevalence of TNBC in West Virginia was 13%, which is similar to the 
nationwide prevalence of 13%.9. Similarly, a there was a larger portion of patients under 40 years 
old within the TNBC population when compared to the non-TNBC population. Also consistent 
with the literature was the increased percentage of non-whites in the TNBC population despite a 
94% white non-Hispanic population prevalence in West Virginia19,9, and confirmation of 
TNBC’s aggressive form and increased risk for metastasis. However, the majority of TNBC 
patients were older adults and there was a significant increased risk for high grade tumor in older 
patients at time of diagnoses with TNBC.  
The novel finding concerning TNBC diagnosis and tumor grade variation by age provides 
opportunity for future research. The numbers are significant and may be due to biological 




disease, or some other factor. The finding warrants additional investigation, perhaps using 
national data.   
We also found that multigene testing was not performed frequently, especially in TNBC patients, 
and the test's frequency decreased with patient age. The cost, difficulty of coverage for testing, 
and limitations of many tests in healthcare make this result unsurprising.  However, the 
increasing benefit of genetic and epigenetic research as well as improvements to the multigene 
test itself may indicate opportunity for change. The data of this project indicates there may be 
opportunity for improved patient outcomes with future research to identify barriers to its clinical 
use. 
New multigene signature testing provides American Joint Committee on Cancer (AJCC) staging 
and molecular subtyping, both valuable tools for improving our ability to classify cancer types 
and generate research data for identifying targeted treatment. Research by Lehman et al 
discovered from retrospective pretreatment biopsies that prediction regarding neoadjuvant 
response to therapy was not only possible but indicated the probability that there were both 
chemotherapeutic sensitive and chemotherapeutic insensitive subtypes in TNBC.28 In addition, 
research from multiple sources of basic science have linked cancer from the breast with the 
upregulation of a gene, protein, or general pathway.29 For example, in 2009, there was 
documentation of upregulation of hexokinase 2 in breast cancer brain metastasis linked with poor 
prognosis.30 Thus, there is indication that multigene testing could assist evaluation of tumor to 
aid typing and prognosis for future breast cancer patients.  Multigene signature testing alone is 
not the complete answer to identify targeted treatment, stratify risks, and improve outcomes of 




and parameters may improve patient stratification for treatment and lead to data for identifying 
targeted treatments.  
Conclusions 
Our research is broad in its evaluation by use of the entire West Virginia breast cancer registry 
data for our research. It is unique in its analysis to identify present evidence of TNBC disease in 
West Virginia and its discussion of testing practice to raise pertinent questions. It is translational 
in its combination of basic science and clinical application perspective.  
TNBC in West Virginia is similar to the nation in its demographic evidence and its aggressive 
nature. Our new finding of TNBC diagnosis and tumor grade variation by age urges future 
research. While the discussion of Multigene signature testing reflects opportunity to evaluate 
policy and practice for its use. Increased efforts are being made to extend multigene testing to 
whole genome evaluation of tumors to bolster the information we glean from tumors.31 
Therefore, increased use of the multigene signature tool may improve our ability to develop 
biomarkers for early identification of disease, targeted treatment, and response to therapy. 
Evaluation regarding our finding of exponential increase of high-grade tumor findings with 
increased age at diagnosis and evaluation of constraints impacting the use of the multigene 
signature test could be beneficial epidemiologic ventures for future research. Our research 
supports the need for increased focus on tumor evaluation and early diagnosis to improve 







CHAPTER FIVE  
Discussion and Translational Significance 
The focused interweaving of this collected work thus far allows for unique understanding of the 
tool of electrophysiology, its significant role in generating functional data to establish a novel 
target for disease treatment in TNBC, and its translational potential to extend the circle of clinical 
translational science with epidemiologic evidence that clinical testing, if properly appraised and 
policy supported, can continue the cycle and turn breast cancer pathology into biomarkers, and ion 
channels into targets. 
This relationship between the electrophysiologic impact of specific ion channels in resting 
membrane potential of the cell lines of triple negative breast cancer and the in vivo impact of 
treatment targeting those ion channels demonstrates the opportunity of electrophysiology to create 
a translational platform from basic science to clinical medicine. Clinical translational science 














The specifics of solutions, measurements, equipment, and technique are listed in detail within the 
individual manuscript projects for reproducibility. This section proposes to present a broader 
understanding of the methods, and why they were the appropriate choice for the project. The 
type of research completed utilized quantitative experimental methodology for the basic science 
and descriptive analysis for the epidemiology. The two methods will be discussed separately.  
Basic Science Methods 
The experimental methodology focused on the basic science research question which 
investigated the apparent contradiction of overexpression of hyperpolarizing channels in a cancer 
cell with a membrane potential that was more depolarized. This led to the hypothesis that those 
overexpressed channels were not active and could be demonstrated using electrophysiology, and 
then exploited to terminate the cancer without harming normal cells. This would fill a knowledge 
gap in the TNBC field where a targeted treatment is urgently needed. The methodological 
approach included the tools of electrophysiology, transfection, cell cycle analysis, in-vivo mouse 
modeling, and the molecular biology to evaluate resected human TNBC tumors. Experimental 
studies were carefully designed with representative samples and controlled variables to allow for 
the research to be reproducible by other researchers. 
 
Methods Terminology: Techniques of Basic Science Research 
Electrophysiology 
The electrophysiology methods were designed to experimentally prove that the overexpressed 
BK channels in TNBC were not functioning (active/open) at physiologic voltage. The resting 




respectively is well documented and indeed TNBC is more depolarized when compared to 
normal breast cells; the standard resting membrane potential for normal breast cells being ~ -
60mV and resting membrane potential for TNBC more depolarized (positive) at ~ -40mV.2,3 To 
evaluate if the channels were functioning whole cell patch clamp technique measured the resting 
membrane potential of TNBC by breaching the cell membrane wall, then creating a giga seal to 
measure its interior charge. This allowed for monitoring the voltage of the membrane potential at 
rest and identifying changes when BK channel openers were added. This would give us the 
overall mV of the entire cell throughout the experiment of homeostasis, BK channel opening, 
drug washout, and BK channel blockade. The cells resting membrane voltages were consistent 
with previous data revealing a depolarized cell at ~-40mV. To experimentally prove the BK 
channels were not functioning (active/open) in this baseline recording, we then added a BK 
channel specific opener. If the channels were not open (active) at baseline and forced open 
(active) with this drug, then our patch clamp should demonstrate a more hyperpolarized (more 
negative) membrane potential when the drug given. The results confirmed our hypothesis and the 
cell demonstrated the hyperpolarized impact of 1000:1 ratio of overexpressed channels. We 
repeated the test at different stimulus voltages since the cell is voltage gated and the impact was 









Diagram 1 BK Channels Forced Open with BK Channel Opener/Activator 
 
Treatment In-Vitro  
These experiments provided a method of visual confirmation to our electrophysiologic data. 
There are characteristic morphology changes in apoptosis seen with hyperpolarization due to loss 
of water following the efflux of K+.4 These experiments provided time lapse video data of the 
TNBC cell shrinkage with application of BK channel opener and subsequent efflux of potassium 
and water. In addition, experiments utilizing ethidium red confirmed significant cell death as 
fluorescent red circular apoptotic morphology replaced the original morphology of elongated 
stretched cells. Finally, the control with normal healthy breast cells demonstrated no significant 
death from the application of BK channel opener. These experiments were specifically designed 
as molecular evidence that the impact was specific to the BK channel which was overexpressed 




have the channels to respond to the drug. This specificity was a key component of the work to 
provide a targeted treatment for TNBC that would not harm healthy cells. 
Transfection In-Vitro (genetic mutation) 
The method of transfection in-vitro provided additional experimental evidence that the 
mechanism of cell death was the BK channel opening. The experiment utilized plasmid 
transfection of a BK channel that was mutated to always remain open thereby mimicking the 
impact of our BK channel opener. The result of the experiment was the same as the result with 
cells treated by BK channel. Significant cell death produced in mutated open BK channel TNBC 
but no significant cell death in wild type without mutation.  
Cell Cycle Changes 
Cell cycle experimental methods were designed as additional confirmation of the halt at G2 
consistent with efflux of potassium from the open BK channels not allowing the cells to recover 
from hyperpolarization to transition into membrane depolarization for mitosis M phase. The 
experiments confirmed accumulation in G2. This method validates the hyperpolarization as 
mechanism. It is well known that cells hyperpolarize in G1/S and on into G2. However, it is at 
the G2/M border where cells must depolarize to begin the M phase. Our experimental methods 
showed the halting at G2 where cells were unable to recover from the hyperpolarization to enter 
M phase. This method design helped codify our electrophysiology data of hyperpolarization via 







Diagram 2: Cell Cycle Halted by BK channel Opener 
 
In-Vivo mouse model 
The design methods for the in-vivo mouse model created systematic treatment of mice by 
mechanisms of tumor injection with BK channel drug to produce a treatment protocol consistent 
with what could be managed in a patient population. Treatments were limited to twice a week 
injections to better simulate patterns of treatment when considering logistics for translation to a 
patient population. The treatment groups were compared to control groups that were not treated 
with the BK channel drug. Design of methods included echocardiogram at baseline and study 
completion to evaluate for impact of the drug on heart function. The method design allowed for 
comparable analysis of tumor volume size between treatment and control groups to determine if 
tumor growth, a measure that has clinical significance, was different between the groups. The 
design not only revealed statistical significance with treatments two times a week which has 
clinical application in its logistical structure, but also fostered promise for future research to 




Translational Human research 
A first step considered in designing a method that created translational human research was the 
need for the experiments to use human resected TNBC tissue, be easily reproduced, and 
foundational for the work. Therefore, the logic was to use common laboratory techniques that 
were feasible and had long standing histories of validation as research tools. The experimental 
methods were then designed to compare human resected triple negative breast cancer tissue by 
western blot and immunohistochemistry. Western blot compared human resected TNBC tissue 
samples with TNBC cell lines to determine if overexpression of this BK channel was evident in 
human resected TNBC tissue. Immunohistochemistry provided visual evidence of the 
overexpression of the BK channel in the human resected TNBC tissue. These methods used  
validated tools with ease of reproducibility to prove BK channel overexpression is a component 
of the macroscopic disease of TNBC not a variant occurring due to variables such as cell line 
immortalization, cell passage, or other confounders. These methods create a solid foundation to 
build additional translational work.  
Epidemiology Methods 
The epidemiology methods utilized descriptive analysis of retrospective data from the West 
Virginia breast cancer registry. A unique tool called effect measure modification was planned in 
the design and methods for its benefit in identifying variables with statistical interaction. The 
dataset was checked for cleanliness and missing data. Then variables were transformed to 
streamlined datasets by clinical standards and analyzed. 
Effect Measure modification 
The method of effect measure modification evaluates an association measure, for example odds 
ratio, to determine if that measure demonstrates changes over values of some other variable.5 




research to lay a transparency, as it were, of one variable over another and determine if there is a 
modification of the effect. This method exposed age at time of diagnosis as an effect measure 
modification. This method is a significant tool for identifying epidemiologic issues that 
otherwise would be overlooked. As an example, this research identified that women under forty 
were 5 times more likely to hear their provider say they had high grade tumor at time of 
diagnosis rather than low grade. With standard methodology this might get overlooked as just a 
feature of aggressive cancer. However, with this method we were able to identify that a patient 
seventy-one was 22 times more likely to hear her provider say she had high grade tumor at time 
of diagnosis rather than low grade. Is this a delay of care issue, significant mutation of the 
cancer, vulnerable population, or some other feature causing this exponential difference?  
In addition, age was also an effect modifier in the multigene signature test conductance. This 
method exposed the underutilization of a clinical tool in a specific, high risk population. To see 
such significant exponential increase of high-risk tumor growth in a patient population receiving 
less evaluation demonstrates the value of this method for identify clinical translational 





















 Literature Review 
 
The literature review is extensive because of the multi-disciplinary requirement of clinical 
translational science. The basic science covers the relevant information regarding the BK 
channel structure and function, the anatomy and physiology of MDA-MB-231 triple negative 
breast cancer (TNBC), as well as TNBC as a disease, while the epidemiology component 
required review of TNBC testing tools, treatment options, and how they are presently used and 
available. In addition, it involved defining clinical translational science and the tool of 
electrophysiology since neither are familiar to all scientists or clinicians. 
BK Channel Structure  
Structure of High-Conductance Calcium-Activated Potassium Channels (BK Kca) which will be 
called BK throughout the rest of this manuscript is a two-unit channel with an alpha and beta 
unit. The alpha unit has several N-terminus isoforms which interact differently with its beta unit.6 
The alpha unit is coded for by the KCNMA1 gene.7,8 There are seven components of this 
transmembrane unit, S0 – S6 with a C-terminus inside the cell, and an N-terminus external that 
reaches toward the beta unit. The S0 has an extra hydrophobic segment at the NH2 terminus 
followed by the S1 – S4 segment which holds the voltage sensitive domains, followed by the S5-
S6 pore domain.9 The internal terminus of the alpha unit called the C-terminus has four 
hydrophobic segments and alternative splicing sites. There are four more regions of the C-
terminus which are a stretch of negatively charged amino acids (aspartates) called the Ca2+ bowl, 
a regulator conductance of potassium (RCK1).  Each α-1 contributes 2 RCK. The second 
regulator conductance of potassium is called the (RCK2). With each alpha contributing two RCK 




There is controversy regarding the beta subunit of the BK channel. Some research credits the 
beta unit with the left shift of conductance seen with different isoforms of the channel while 
others credit calcium as a modulator added to voltage rather than the structure of the beta unit.11,9 
In addition to the controversy, there are four beta units coded by the KCNMB3 gene that 
function as auxiliary, β1, β2, β3, and β4 to the KCNMA alpha subunit.12  Of specific interest to 
clinical translational medicine is that mouse models are often used of necessity and the β3 
subunit in mice shares only 62.3% amino acid identity with humans. By contrast the, β1, β2, and 
β4 have a greater consistency of 83 – 95% 12  Channel complexity with alternate beta subunit 
options that can modify an already variable alpha subunit reveals the need for functional 
evaluation of channels.11  
The pore unit of the BK channel is part of the alpha unit. It is a hemotetramer and its identical 
four subunit complex demonstrates its association rather than covalent bonding between the 
subunits. This region is an external part of the channel and represents the area where 
tetraethylammonium (TEA), Iberiotoxin (IbTX), and Charybdotoxin (CTX) work when used as 
inhibitors of the channel.13,14,9  The turret between S5 and the pore helix of the BK channel has 
more residues than other potassium channels and they can reorient to impact function of the 
channel.14,15 
The structure of the BK channel involves recognizing many facets of the channel including 
molecular weight and proteolytic decay. The alpha unit has 130 kilodalton (kDa) molecular 
weight while the beta unit ranges from 20 – 30 kDa. This creates a molecular weight of 160kDa 
for the complete channel without post-translational changes or proteolytic decay.16 Early 
research indicates that there is discrepancy in the kDa molecular weight for the alpha unit in 




and reproducible proteolytic decay from its 125-130kDa full length.17,16   There are distinct 
positions within the C-terminus of the alpha unit coded for by KCNMA1 where proteolysis 
occurs. This creates a product with a 90kDa, 65kDa polypeptide in addition to numerous smaller 
fragments such as 25kDa.17 
BK Channel Function  
There are many components to ion channel function. However, the one most relevant function 
for this ion channel is its role in impacting resting membrane potential. Membrane potential has 
three phases sometimes considered four phases; polarization, depolarization, hyperpolarization, 
are the three main phases while repolarization is a return to polarization state.  The BK channel 
function in membrane potential is hyperpolarization. The hyperpolarization has different impacts 
depending on the tissue location of the BK channel. In neurologic systems with excitable cells 
the hyperpolarization can reduce firing of action potentials. In vascular tissue the BK channel 
function demonstrates vascular dilation18 and in non-excitable cells the hyperpolarization 
impacts resting membrane potential19, but little is understood about what that means for the cell. 
This led to our query of its role and possible target potential in triple negative breast cancer 
where it is overexpressed. These questions along with evidence from structure that sensitivity of 
the alpha unit to shifting the mid-point activation to more hyperpolarized potentials17 regardless 
of whether calcium or beta unit is the cause led to recognition of the knowledge gap. 
Further literature review led to the vascular impact of the BK channel. “BKCa channels serve as 
a counter-regulatory mechanism by reverting vasoconstriction, particularly in the intense 
myogenic constriction of resistance vessels exposed to high intraluminal pressures.”20 This leads 




Anatomy and Physiology of MDA MB 231 TNBC  
ORIGIN 
MDA MB 231 is a cell line immortalized and established in the 1970’s from an original older 
cell line called BT20 which was established in the 1950’s from a pleural effusion.22 Although 
this cell line was developed from a pleural effusion there is significant evidence that cell lines 
maintain the transcriptional and biological heterogeneity from their primary tumors.23,24 The 
value of cell lines persists even as new in vitro models with induced pluripotent stem cells 
(iPSCs) develop. MDA MB 231 was not characterized as TNBC in early years due to the lack of 
knowledge regarding the role of hormone receptors in breast cancer.  More specific details of the 
maintenance of expression pattens is noted for the MDA MB 231 cell line due to its luminal-
basal TNBC subtype distinction.24 There are several cell lines utilized in the research to confirm 
results were not in one cell line or subtype only. The HCC1143 cell line was used and it is Basal 
A subtype also called Basal Like.25  In addition, SUM 159 cell line was used which is similar to 
MDA MB 231 by subtype with both classified as Basal B or Claudin low.26 Some researchers 
call Basal A and Basal B lines triple negative A and triple negative B.26 The subtyping of TNBC 
can be confusing due to multiple names given to the same classification as well as continued 
controversy in typing TNBC. Newest classifications are Basal-like 1, Basal-like 2, 
Immunomodulatory, Mesenchymal, Mesenchymal Stem-like, and Luminal Androgen 
Receptor27,28 and relate to genetic profiles for their subtype classification.  
The basal-like 1 subtype has increased cell cycle and DNA damage response gene expression.29 
The basal-like 2 subtype is characterized more by growth factor signaling and myoepithelial 
marker enrichment.29 The immunomodulatory(IM) subtype, as expected is characterized by 
enrichment of genes encoding for immune function such as those for immune antigens, 




both the tumor and infiltrating lymphocytes. The IM subtype has the largest lymphocyte 
percentage at 38%.29,30  Mesenchymal has the lowest at 9% while basal-like 2 comes in at 23% 
followed by mesenchymal stem-like at 21%, luminal androgen receptor at 17%, and basal-like 1 
at 15%.29 
As expected, mesenchymal and mesenchymal stem-like share similarities with elevated 
expression of growth factor pathways. However, mesenchymal stem-like shows decreased 
expression of genes involved in proliferation. 29 
Luminal androgen receptor subtype is characterized by luminal gene expression and is 
predominantly propelled by the androgen receptor.29 
The scientific and clinical communities have struggled to classify the subtypes of TNBC because 
of these genetic variations that are overlaid with relapse-free survival differences, metastatic 
differences, histological variation, and response to therapy variation. For example, basal-like 1 
demonstrates higher grade, lower stage with increased likelihood of complete response to 
treatment, as well as overall increased relapse free survival. Luminal androgen receptor tumors 
demonstrate increased regional spread, their distant metastases is inclined to bone, and their 
histology, which is commonly lobular carcinoma, is exclusive to this particular subtype of 
TNBC.29  
Mesenchymal tumors are predisposed to metastasize to lung. Their histology is metaplastic 
carcinoma similar to basal-like 2, yet again is different in other capacities to warrant a separate 
classification of the two.29  
Metabolic variation based on phosphorylation profile raised some additional molecular 
characterization points of consideration for classification.31,32,33,34  





The morphology of the MDA MB 231 cell line we used demonstrated consistent morphology in 
media-based incubation. The characteristic morphology of  MDA MB 231 has a 200-600µm2 
spreading area35 in gel based culture.  The cells elongate along arbitrary lines.36 These 
characteristics were helpful in utilization of the cells for patch clamp. The stretch allowed for 
examination of the cell under the microscope light to evaluate by shadow lines for the best point 
for an electrophysiology patch. In addition, the specific stretch and elongation pattern of the cell 
made the evidence of shrinkage and rounding, during treatment, as an early sign of apoptosis 
significantly evident. 
MEMBRANE POTENTIAL 
Membrane potential at the cellular level is key to this research. The electrophysiology, which is 
the electrical function of a normal biological organism, identifies why the overexpressed BK ion 
channel is not functional at physiologic voltages, and can be a potential target against TNBC.  
To discuss membrane potential, it is necessary to discuss how cells mimic an electrical circuit.  
 






Diagram 4: Understanding Voltage and Membrane Potential 
Electrical charge +/ – moves from inside to outside the cell or vice-versa and creates the 
difference which we measure as voltage. 
 
Terms: 
Coulombs – The coulomb is the standard unit of electric charge. Electrons are too small to be 
used as the measure of electric charge. Therefore, we identify a collection of them as an electric 
charge. That collection is defined as the number of electrons that can pass through a set point in 
one second. The number of electrons that can do that is 6.24 x 1018 electrons or one coulomb.   
Ampere – The ampere is the unit of electric current and is expressed as the flow of one coulomb 
(6.24 x 1018 electrons) per second. Therefore, 1 ampere (amp) = 1 coulomb per second. 
In electrophysiology patch clamp measurements are in picoamps (1 picoamp = 1 x 10-12 amp).  
Voltage – The force of potential difference. One volt is one joule of energy (work done by the 
force of that potential difference) per coulomb. The cell membrane potential is measured in mV 
in whole cell patch clamp. Therefore, we can measure the force of potential difference across 
that cell membrane and identify its quantitative number in mV. These mV represent the cell 




discussed first as an action potential in a cell then discussed in regards to changes in resting 
potential. The Hodgkin cycle described in the original work of 1952 conveys the idea well. The 
opening of sodium (Na) channels moves the cell towards depolarization (more positive) by 
moving Na into the cell. Then as the potassium (K) channels open K moves out of the cell 
causing hyperpolarization (more negative) membrane potential before returning to the 
physiologic or normal resting membrane potential.37 
 
Diagram 5: Membrane Potential: From Threshold to Hyperpolarization 
 
The importance of this in relation to the TNBC work is the electrophysiologic evidence that 
TNBC has a resting membrane potential that is more depolarized (more positive) than normal 
breast cells. This increased depolarization is associated with increased proliferation which is 






Diagram 6: Resting Membrane potential TNBC vs Normal Cells 
 
Our research confirmed this increased depolarization of the resting membrane potential of TNBC 
compared to normal breast cells. In addition, our novel discovery that the overexpressed BK 
channel in TNBC was not functioning (active) at physiologic voltage led to our hypothesis that 
the overexpression of the hyperpolarizing BK channel was not impacting the cell; and this could 
pose an opportunity to activate those channels and severely hyperpolarize and thereby kill the 
TNBC cells by efflux of potassium.   
 
TNBC the Disease 
TNBC is a devastating disease with a lower five-year survival rate, increased risk for recurrence, 
and highest rate for brain metastases of all breast cancers.38,39,40,41 TNBC is estrogen, 
progesterone, and human epidermal growth factor receptor (HER2) negative. This creates a 
significant challenge for oncologists owing to the recurrence and metastasis which result in a 
poor prognosis.42 






Knowledge about cancer treatment for TNBC is still maturing. TNBCs are transcriptionally 
heterogeneous and can be grouped into subtypes with vastly differing biology and responses to 
chemotherapy and targeted therapies.43 Later research by Lehmann discusses the identified 
TNBC cell lines representative of each subtype and demonstrated differential sensitivity to 
alkylating agent cisplatin29 which raises new purpose for some of the testing discussed in the 
epidemiology project. These are treatment variations that were unknown several years ago.  
“In a prior retrospective analysis of patient pretreatment biopsies, TNBC type molecular 
subtypes were predictive of response to neoadjuvant anthracycline and cyclophosphamide 
followed by taxane (ACT), with BL1 subtype tumors exhibitng the highest pCR (52%) and BL2 
and LAR subtypes the lowest (0 and 10%, respectively). These results suggest that certain TNBC 
subtypes are intrinsically sensitive or insensitive to neoadjuvant chemotherapy.”29 
Conventional therapies employed in treatment of TNBC suffer from issues of poor 
bioavailability, poor cellular uptake, resistance, and undesirable off-site toxicities.42  
Surgery 
Surgical resection is standard care for all breast cancer. However, the decision for lumpectomy 
versus mastectomy often discussed with estrogen positive breast cancer patients and others is not 
a similar discussion with patients diagnosed with triple negative breast cancer. Although early 
literature up through around 2010 discusses breast conserving surgery as an option in TNBC, it is 
not as commonly seen after 2010 accept with adjuvant radiation therapy.44,45 The topic is 
controversial and many clinicians continue to recommend full mastectomy. The aggressive 
nature, heterogeneity, and lack of treatment options increasingly leads to mastectomy as only 




signature test could afford us valuable information about this difficult disease allowing us to 
create better options for care via the data produced to basic science for discovery of biomarkers, 
and treatment targets.  
Radiation 
Radiation therapy has found an increasing role in TNBC treatments with research projects that 
demonstrated improved five year survival and disease free rates in patients receiving radiation as 
neoadjuvant therapy.45,46 It is increasingly evident that radiation as neoadjuvant therapy is 
beneficial in TNBC patients receiving either breast conservative therapy or mastectomy and it is 
the molecular information regarding the biological characterization of subtypes that are 
improving clinician decision making for neoadjuvant therapy.46  These principles once again 
support the evidence of the epidemiology study that improved utilization of molecular testing 
such as multigene signature tests could dramatically change the landscape of treatment options 
and decision making in TNBC by generating the data that assists in subtyping TNBC, and 
identifying basic science research targets for neoadjuvant treatment in this aggressive disease.  
 
Breast Cancer Testing 
 
Breast cancer testing is documented across the United States by established protocols from 
Surveillance, Epidemiology, and End Results (SEER). SEER started in five states in 1973 and 
now has expanded across the United States.47 West Virginia is one of the last remaining states 
that do not report their data to SEER. However, the West Virginia cancer registry is set up based 
on the SEER protocols. The site specific cofactors listed below are from the West Virginia 
registry and have been placed in a table format with appropriate links for details regarding their 
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Figures and Tables 
Temporal Lobe Epilepsy, Stroke, and Traumatic Brain Injury: Mechanisms of 
Hyperpolarized, Depolarized, and Flow-Through Ion Channels Utilized as Tri-Coordinate 
Biomarkers of Electrophysiologic Dysfunction 
 
Figure 1 The casting of the entire vascular network 1A in a 24-month old male wild type mouse. 
The cast created with polyurethane resin and image acquired with micro CT system for 
visualization of collateral vasculature structure (Picture courtesy of Dominic Quintana, 
Neuroscience Department, West Virginia University). In 1B Computed Tomography 
Angiography of the normal single side internal carotid end artery system in human. The internal 
carotid artery supplies the anterior circulation to the brain and includes the middle cerebral artery 
(MCA) commonly associated with stroke and the anterior choroidal artery, which is a feeding 
vessel, from the anterior system, the hippocampal region associated with the sclerosis of 
temporal lobe epilepsy. In 1C the anterior choroidal artery in humans is the only artery branch 
feeding the hippocampus from the anterior system, apart from the recurrent artery of heubner. 
The mouse has a more collateral reach to the hippocampus possibly contributing some 





Figure 2 The glass pipette as electrode 2A in the recording bath where the astrocyte 2B is 
adhered to the coverslip. 2C demonstrates the patch between the electrode and the astrocyte 
under the microscope. Finally, 2D is an example of real time electrical current received from a 
cell. 
 
Figure 3 In 3A the variability of the pyramidal cells is shown by the CA1 and CA3 pyramidal 
neurons compared to the Layer V (LV) pyramidal neuron when you look at where and how the 
branching occurs. The LV pyramidal neuron has a streamline look and reaches through all six 




apical branching are designed for their local purpose. In 3C the arrows indicate the location of 
the soma where patch clamp recording gives the reading of the resting membrane potential of the 
entire cell. Picture reprinted by permission from Macmillan Publishers Ltd: [Nature Reviews 
Neuroscience] [21], copyright (2008). Finally, in 3D, the ramp protocol, and 3E, the pulse 
protocol, you see examples of recordings received from a cell with two different protocols in the 
whole cell patch technique. Protocol examples are from our research lab at West Virginia 
University. 
 
Figure 4 Nernst equation calculation for Chloride demonstrates the electrophysiologic alteration 
of membrane potential possible with fluctuations of Cl− in conditions such as ratio shift of 
NKCC1 to KCC2. Their correct ratio is necessary for neutrality of charge. Repeat the calculation 
on your own by changing the outside and inside molarity to demonstrate what can happen if the 





Table 1 The voltage measurements from Della Santina [44] in their work with HCN1 channels 
in the retina converted to a table to demonstrate the value of monitoring Ih current of the HCN1 
channel. The results indicate the channel in response to hyperpolarization and depolarization and 

















Opening Large-Conductance Potassium Channels Selectively Induced Cell Death of Triple-




Figure 1 KCNMA1 gene expression in five molecular subtypes of breast cancer. Each dot 
represents one patient. Gene expression levels are presented as FPKM in log2 expression. Red dots 
are basal-like triple-negative (TN) breast cancer patients. Blue dotted line indicates KCNMA1 





Figure 2 Protein expression of BK channel -subunit (forming the functional channel) in 
TNBC cells and patient tissues. (A) Western blots with antibody, M: marker, MDA231: MDA-
MB-231 cells (cell positive control), Normal: normal primary breast tissue, TNBC: TNBC patient 
tissue, MB: mouse brain (tissue positive control). -actin was used as a loading control. (B) 
Western blots with antibody and antigen, confirming signals detected by the antibody in (A). (B) 
Quantitative expression levels of BK channel proteins normalized to -actin (n=4-6). Unpaired t 
test was performed. Two-tailed p=0.0002, t=0.8172. (D) Western blots using a BK channel protein 






Figure 3 Biophysical properties of BK channels in MDA-MB-231 cells. (A) BK channel 
currents elicited by depolarizing pulses ranging from -40mV to +50mV in 10mV increment, 
pulse protocol is shown below. (B) BK channel conductance, G, – voltage relationship in the 
absence (black) and presence (red) of 0.1 M IbTX (n=8). (C) Effects of BMS-191011 and IbTX 






Figure 4 BK channel openers induced cell death in TNBC cell lines. (A) BMS-191011 (20 
M) induced cell death on normal breast cells (MCF10A, dark), ER+ breast cancer cells (MCF7, 
grey), and TNBC cells (MDA-MB-231, red) (n=5). One-way ANOVA was performed, 
p<0.0001, F=65.38. (B) Time- and concentration-dependent effects of NS11021 on growth of 
MDA-MB-231 cells (n=6). Two-way ANOVA was performed, p<0.0001, F=66.67, DF=9. (B) 
Time-dependent effect of BMS-191011 (20 M) on growth of SUM159 cells (n=4). Two-way 
ANOVA was performed, p<0.0001, F=618.9, DF=6. (D) Time-dependent effect of BMS-191011 





Figure 5 BMS-191011 induced activation of caspase-3 in MDA-MB-231. Using caspase-3/7 
green dye, fluorescence was detected after incubation of 10 M BMS-191011 for three days (B). 
Light image is shown in (A). Scale bar: 20m. Using immunoblots, caspase-3 was detected in 
three TNBC cell lines (MDA-MB-231, HCC1143, SUM159) (C). Cleaved caspase-3 was 
detected after BMS-191011 treatment (D, M-marker, red arrow indicates pro-caspase 3, black 
arrow indicates cleaved active caspase 3). 
 
 
Figure 6 BMS-191011 induced arrest in S/G2 phases of MDA-MB-231. (A): No treatment 
(control), (B): Drug treatment for 24h, (C): Drug treatment for 48h. Blue: G1 phase; Green: S 





Figure 7 Slowing of MDA-MB-231 xenograft tumor by BK channel opener. (A): Three 
paired-tumors of similar sizes (C1/T1, C2/T2, C3/T3) are shown to illustrate the inhibitory 
effects of BMS-191011 in tumor growth. Ultrasound imaging was performed once a week to 
calculate the tumor volume (mm3) for four weeks. A reconstruction of the tumor volume from 
ultrasound imaging is shown in the inset. (B): Average tumor volume in control (n=8) and 

































Supplemental Fig. 1 Immunohistochemistry of BK channels in TNBC patient 
tissues (IHC). (a) normal breast tissue, (b) TNBC tissue (BK channel expression 
indicated by brown color, see Methods), (c) Percentage of staining area averaged from 








Supplemental Fig. 2 BMS-191011 on human breast cancer cell lines. Upper 
panels show the bright-field images, lower panels show the dead cells labelled by EthD- 
1 dye (red). BMS-191011 (20 M) treatment of MCF10A (left), MDA-MB-231 (middle), 








Supplemental Fig. 3 Concentration-dependent effects of NS11021 on MDA-MB- 
231 after 5 days. Upper panels show the effects of NS11021 in bright field, lower 
panels show the dead cells labelled by EthD-1 dye (red). Scale bar: 20 m. 
 
 






Supplemental Fig. 4 Concentration-dependent effects of BMS-191011 on 
SUM159 after 5 days. Upper panels show the bright-field images, lower panels show 
the dead cells labelled by EthD-1 dye (red). Scale bar: 20 m. 
 
 




Supplemental Fig. 5 BMS-191011 on HCC1143. Upper panels show the effects of 
BMS-191011, lower panels show the dead cells labelled by EthD-1 dye (red). Left: 
control; Right: one day after 10 M BMS-191011 treatment. Scale bar: 20 m. 
 
 







Supplemental Fig. 6 DMSO on HCC1143. DMSO (5 l, corresponding to the 
volume used for 50 M BMS-191011) on HCC1143. Upper: after 48hr; Lower: after 96hr. 
Left: light image, Right: dead cells labelled by EthD-1 dye (red). Scale bar: 20 m. 
 
 






Supplemental Fig. 7 MDA-MB-231 cell death induced by a constitutively open 
BK channel mutant, A313D. WT: wild-type BK channel, A313D: mutant channel, GFP: 
GFP plasmid, *: p&lt;0.05. 
 
 




Supplemental Fig. 8 Three images corresponding to starting time point (control, t=0) (A), 
20min (B), and 60min (C) after BMS-191011 (1 M) application are shown. Red arrows 
illustrate the representative cells undergoing morphological changes during the time 
course of BMS-191011. 
 
 







Supplemental Fig. 9 Prevention of MDA-MB-231 cells migration by BMS- 
191011. In the absence of BK channel opener (Con) (A), cells migrated to fill the gap 
(“wound”) after 4hrs (B). Low concentration (100nM) of BK-191011 (C) prevented the 
“heal” (cells filling the gap) after 4hrs (D). Scratch is defined by the space within two red 
lines. Curved red line indicates the marker (shadowed area) used to identify the location 
of the scratch. Scale bar: 20 m. 
 
 






Supplemental Fig. 10 DMSO does not affect cell cycle in MDA-MB-231. a: no 
DMSO treatment, b: DMSO treatment after 24h. Blue: G1 phase; Green: S phase; Red: 
G2 phase. Count: amount of cells, PI-A: fluorescence intensity. 
 
 




Supplemental Fig. 11 BK channel opener does not alter cardiac functions in 
NSG xenograft model. Results of three control and four treated mice were compared. C: control, 




corrected left ventricular mass (mg), CO: cardiac output (mL/min). Unpaired t-Test was 
performed. For HR, p=0.6621, t=0.4595; For EF, p=0.5281, t=0.6695; For LV, p=0.5209, 
t=0.6816; For CO, p=0.9443, t=0.07285. 
 
 




Supplemental Fig. 12 Supplemental Figure 13: BK channel opener induced cell death in MDA-
MB-231, but not in cardiac myocytes. A: MDA-MB-231 stable cell line with DsRed inserted. B: 
H9c2 cardiac myocytes. C: co-culture of MDA-MB-231/DsRed cells (red) with H9c2 
cardiac myocytes (gray) after one-day treatment of BMS-191011 (20 M). D: co-culture 
of MDA-MB-231/DsRed cells (red) with H9c2 cardiac myocytes (gray) after six-day 


















































































This composition of three projects reflects the perspective of clinical translational science. The 
first work reviews the use of electrophysiology in the microscopic and macroscopic world, 
demonstrates a novel means of connecting them with this tool, and discusses opportunities for 
future research on a broad scale. The second work tackles application of electrophysiology to 
identify a novel targeted treatment for an aggressive breast cancer disease, triple negative breast 
cancer. Finally, the electrophysiology discovery guides the hypothesis for an epidemiology study 
to determine the use of molecular signature testing for triple negative breast cancer in the West 
Virginia population to prepare the way for future research identifying biomarkers and targets for 
this disease. 
Electrophysiology in Clinical Translational Science creates novel opportunity for translating 
basic science to the clinic by virtue of a tool that communicates data across the chasm between 
the microscopic scale of bench science and the macroscopic scale of clinical application. This 
tool creates novel application of electrophysiology for disease evaluation across measures of 
scale. It provides functional evaluation of genetic data regarding over-expressed and under-
expressed ion channels to guide discovery for disease treatment. Finally, it advances 
epidemiologic discovery by generation of novel insight for researching disease in the population. 
Utilizing electrophysiology to bridge the gap between microscopic basic science discovery and 
macroscopic clinical application is a difficult challenge. This project seeks to recommend growth 
in the use of electrophysiology beyond the boundaries of this work, demonstrate the novel use of 
it in development of targeted treatment for a disease, and exhibit its novel provision to 




In addition, the ability of electrophysiology in ion channel evaluation to resolve a significant 
contradiction in the literature of BK ion channels demonstrates its formidable ability to give 
functional quantitative answers to the ambiguity of genetic expression. Prior to this research 
controversial results of the BK channel in breast cancer proliferation and treatment were blatant. 
Khaitan et al in his 2009 work demonstrated that metastatic brain cancer from breast 
overexpressed BK channels more than metastatic cancer from the breast to other organs. From 
this he concluded that the migration and invasion was due to the increase of BK channel and that 
blocking the channel would be an effective way to impact this process.48 However, what was 
overlooked is the function of the channel.  Our research has demonstrated that the BK channel is 
not open (active) at physiologic voltage therefore inhibition of a closed channel is unlikely to 
produce the impact anticipated.  
Indeed, research by additional scientist have demonstrated that inhibition did not have the 
anticipated impact.  Schickling’s discussion in Oncogene Report regarding their equivocal results 
caused him to note that BK channels may be pro or against growth.49 The significant contribution 
of this dissertation to facilitate a final answer to this controversy not only gives perspective to the 
cause of the contradictions (ie…not evaluating channel function) but also provides solid, 
reproducible techniques for future ion channel research in diseases with over and under 
expressed ion channels. 
Finally, the in vitro altered homeostasis in ion channel targeting of a single cell of human triple 
negative breast cancer and the in vivo impact of its application in mice can be discussed with 
clinicians using the language of electrophysiology regarding polarization, depolarization, and 
hyperpolarization, a language they already speak with EKG analysis in their daily routines. It is 




channels are forced open and potassium efflux leads to apoptosis. The evidence for potassium 
efflux as mechanism for apoptosis is well demonstrated.50  Our research utilizing 
electrophysiology demonstrates hyperpolarization to confirm potassium efflux via the BK 
channel as mechanism of apoptosis in triple negative breast cancer. Therefore, this genetic 
variation of overexpression can be exploited to target the disease. Electrophysiology gives 
functional answers to the decades of accumulated genetic research. Patch clamp, as an 
electrophysiology tool speaks in the physics language of electrical current which translates from 
basic science to the clinic.  
The language barrier electrophysiology bridges between basic science and clinical medicine 
offers a significant opportunity to utilize a tool that will give functional data to our growing 
collection of genetic data that can be translated to clinical application. The initial manuscript in 
this dissertation work discussed interconnected evaluations of multiple ions and ion channels that 
is still very difficult to do and will require extensive modeling to fully develop. However, the 
second manuscript in this dissertation demonstrates a beginning step in that direction by utilizing 
a transmembrane channel that operates by interaction with two ions; the ion transported across 
the membrane -potassium - and the ion that impacts its gating, calcium. The evidence of the BK 
channel to selectively kill triple negative breast cancer in-vitro and halt tumor growth in-vivo is a 
novel discovery for targeted treatment of triple negative breast cancer with BK channel openers 
that addresses the contradiction of previous research which only considered its overexpression 
not its electrophysiologic activity at physiologic states. This new evidence demonstrates BK 
channel opportunity as a targeted treatment and confirms the role of calcium in proliferation 
rather than the BK channel which is simply impacted by the increased calcium. Finally, the third 




test, which can identify molecular biology variants like overexpression, and response to 
treatment. Together these create an opportunity for explosive translational growth as we wield 
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Clinical Translational Science Definition and Purpose 
The definition and purpose of Clinical Translational Science is still evolving. As any new 
science field, the parameters are set and then adjusted as the field matures. There are five phases 
of translational research defined by the clinical and translational scientific community (T0-T4).51 
Translational research is a multi-directional process which integrates multidisciplined science 
across populations, basic science, policy, and clinical application.52 The National Center for 
Advancing Translational Science speaks of the developing nature of clinical translational 
science. “At all stages of the spectrum, NCATS develops new approaches, demonstrates their 
usefulness and disseminates the findings. Patient involvement is a critical feature of all stages in 
translation.”53 The long-term goal of this project is to advance clinical and translational science 
by demonstrating electrophysiology utilizes a language of physics which speaks fluently from 
the microscopic to the macroscopic, reaching from the atomic to the cosmic to address human 
questions in basic science, and clinical medicine.. The initial discussion and first publication 
address the complexity of the problem translational science faces and the opportunity 
electrophysiology creates to generate mechanisms for evaluation. The broad scale is then 
narrowed to illustrate this principle through the second paper which encompasses the basic 
science research, pre-clinical research, and the clinical research by cell line in-vitro work, 
xenograft mouse model work, and human resected cancer tumor work respectively; this gives 
evidence for the functional role of BK (big conductance potassium) channels for targeted 
treatment in triple negative breast cancer (TNBC). The third discussion continues the precedent 
for research translation from basic science to clinical practice by epidemiology research to 
evaluate TNBC in our local patient population of West Virginia utilizing the West Virginia 




reference to generate the collaborative radiation neoadjuvant treatment with targeted ion 
channels in mice, followed by randomized clinical trials targeting BK ion channels as 
neoadjuvant treatment with radiation prior to tumor resection in patients with TNBC. In 
accordance with the goals of the NIH National Center for Advancing Translational Science this 
research aims to harmonize the diverse measures of scale between molecular biology and clinical 
medicine. This project completes both T0, T1, and T4 research with defined direction for future 
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